Original Article

Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer

David Esrig, Donald Elmajian, Susan Groshen, John A. Freeman, John P. Stein, Su-Chiu Chen, Peter W. Nichols, Donald G. Skinner, Peter A. Jones, and Richard J. Cote

N Engl J Med 1994; 331:1259-1264November 10, 1994

Abstract

Background

We have previously demonstrated a strong association between nuclear accumulation of p53 protein, as determined by immunohistochemical analysis, and mutations in the p53 gene. The purpose of this study was to determine the relation between nuclear accumulation of p53 and tumor progression in transitional-cell carcinoma of the bladder.

Full Text of Background...

Methods

Histologic specimens of transitional-cell carcinoma of the bladder (stages Pa, noninvasive disease, to P4, disease with direct extension into adjacent organs or structures) from 243 patients who were treated by radical cystectomy were examined for the immunohistochemical detection of p53 protein. Nuclear p53 reactivity was then analyzed in relation to time to recurrence and overall survival.

Full Text of Methods...

Results

The detection of nuclear p53 was significantly associated with an increased risk of recurrence of bladder cancer (P<0.001) and with decreased overall survival (P<0.001). In patients with cancer confined to the bladder, the rates of recurrence for stage P1, P2, and P3a tumors that had no detectable nuclear p53 reactivity at five years were 7, 12, and 11 percent, respectively, as compared with 62, 56, and 80 percent, respectively, for tumors that had p53 immunoreactivity. Similar results were obtained when the presence or absence of p53 in the nuclei of the tumor cells was studied in relation to overall survival. In a multivariable analysis stratified according to grade, pathological stage, and lymph-node status, nuclear p53 status was an independent predictor (and in cancer confined to the bladder, the only independent predictor) of recurrence and overall survival (P<0.001).

Full Text of Results...

Conclusions

In patients with transitional-cell carcinoma confined to the bladder, an accumulation of p53 in the tumor-cell nuclei detected by immunohistochemical methods predicts a significantly increased risk of recurrence and death, independently of tumor grade, stage, and lymph-node status. Patients with transitional-cell carcinoma confined to the bladder that demonstrates nuclear p53 reactivity should be considered for protocols of adjuvant treatment.

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 1Immunohistochemical Detection of p53 Protein in the Nuclei of Transitional-Cell Carcinomas of the Bladder with the Anti-p53 Monoclonal Antibody PAb1801.

Figure 2Probability of Remaining Relapse-free in 243 Patients with Bladder Cancer and either p53-Positive or p53-Negative Tumors.

Article Activity

319 articles have cited this article

Article

Mutations of the p53 gene are the most common genetic defect in human tumors1. The p53 gene functions as a tumor-suppressor gene and more specifically as a cell-cycle regulator2. Levels of p53 protein increase in response to damage to DNA, arresting the cell cycle and allowing time for the repair of DNA.

Mutations of the p53 gene occur in a high percentage of invasive transitional-cell carcinomas of the bladder3 and appear to be an early event in the formation of carcinoma in situ4. They are much less frequent in noninvasive papillary tumors5,6. Mutations of the p53 gene and nuclear accumulation of p53 protein are associated with the grade and stage of bladder cancer5 and may be important in the multistep progression of bladder cancer7-9. The immunohistochemical detection of the protein, which exploits the difference in life span between mutated and wild-type p53, has been shown to correlate strongly with mutations of the p53 gene in bladder cancer5.

The primary factors used in determining the clinical treatment of patients with early-stage bladder cancer are the depth of tumor invasion, the tumor grade, and the presence or absence of lymph-node metastases. Radical cystectomy is a generally accepted treatment for patients with invasive cancer confined to the bladder, particularly when there is evidence of muscle invasion10. Surgical treatment is curative in a substantial proportion of such patients, but in a large number incurable metastatic disease appears after surgery. Adjuvant therapy (including chemotherapy and radiation therapy) is under investigation in this setting, and shows encouraging results11,12. It may thus be important to distinguish patients for whom surgery alone is adequate and who can avoid the morbidity and expense of adjuvant therapy from patients who might benefit from both surgery and additional treatment.

In the present study we sought to determine whether a nuclear accumulation of p53 is an important factor in predicting the clinical behavior of bladder cancer. Previous work has suggested that alterations of p53 can predict disease progression in superficially invasive bladder cancer13. However, a study of patients with bladder cancer who received a variety of treatments suggested that nuclear accumulation of p53 is not a predictor of disease progression that is independent of clinical stage and the rate of proliferation of the tumor cells14. We demonstrate, in 243 patients with bladder cancer treated by radical cystectomy, that nuclear accumulation of p53 identifies transitional-cell carcinomas with a propensity for progression that is independent of tumor grade and stage.

Methods

Population of Patients

We studied 243 patients who underwent radical cystectomy, pelvic-lymph-node dissection, and urinary diversion at the Kenneth Norris Jr. Comprehensive Cancer Center. To assess the association between nuclear accumulation of p53 and clinical outcome, we included all patients with transitional-cell carcinoma treated by radical cystectomy from April 1983 through June 1987 for whom follow-up data and tumor samples from the cystectomy specimens (preserved in archival paraffin-embedded tissue blocks) were available. An additional 33 patients who underwent cystectomy between July 1987 and December 1988 were studied in order to increase the number of patients with cancer confined to the bladder. The study also included 53 patients described previously whose tumors underwent both molecular and immunohistochemical analysis for p535. Thus, of the entire group of 243 patients, 190 had not previously been evaluated for nuclear accumulation of p53. Patients with pure adenocarcinoma, squamous-cell carcinoma, or small-cell carcinoma of the bladder were excluded. The median age of all patients was 63 years (range, 49 to 83); 77 percent were men, and 23 percent were women.

Clinical and Pathological Evaluation

The indications for radical cystectomy included invasion of muscle or prostate stroma by the tumor; high-grade, superficially invasive tumors associated with carcinoma in situ; carcinoma in situ refractory to intravesical chemotherapy or immunotherapy; and recurrent multifocal disease after conservative therapy. None of the patients received pelvic irradiation or systemic chemotherapy before surgery. All the specimens included in this study were transitional-cell carcinomas; a minority demonstrated glandular or squamous differentiation. The histologic grading was performed according to the method of Bergkvist et al.,15 and the pathological staging was done according to the tumor-node-metastasis classification16. All tumors were reevaluated for histologic grade by two of the investigators. Among the 243 tumors, 11 were classified histologically as grade 2, 157 as grade 3, and 75 as grade 4. Five tumors were classified as stage Pa (noninvasive papillary tumors), 11 as stage Pis (carcinoma in situ), 50 as stage P1 (superficial invasion), 32 as stage P2 (superficial invasion into muscularis propria), 35 as stage P3a (deep invasion into muscularis propria), 68 as stage P3b (invasion into perivesicular fat), and 42 as stage P4 (direct extension into adjacent organs or structures). Sixty-six patients were found on pathological examination to have metastatic disease in the pelvic lymph nodes. None of the patients had distant metastatic disease at the time of cystectomy. Forty-one patients received systemic chemotherapy after surgery, either cisplatin, cyclophosphamide, and doxorubicin or methotrexate, vinblastine, doxorubicin, and cisplatin. The median follow-up for the 243 patients was 6.0 years, with 81 percent having at least 3 years of follow-up. The patients were seen at three-month intervals during the first postoperative year, every four months during the second year, and every year thereafter. Follow-up consisted of a biochemical profile, chest radiography, and physical examination. A computed tomographic scan or bone scan was performed to confirm suspected recurrences of disease. Data on recurrences of transitional-cell carcinoma and causes of death were obtained from office and hospital records.

Monoclonal Antibodies and Immunohistochemical Analysis

Five-micrometer sections of archival formalin-fixed, paraffin-embedded tissue were placed on slides coated with poly-l-lysine (Sigma, St. Louis). The immunohistochemical procedure was performed as described elsewhere5. In brief, after deparaffinization and blocking of endogenous peroxidase, the anti-p53 mouse monoclonal antibody PAb1801 (IgG1 class, 1:10 dilution, Biogenex, San Ramon, Calif.) was incubated overnight with tissue at 4 °C. PAb1801 recognizes the p53 protein at a denaturation-resistant epitope corresponding to amino acids 32 through 79. Tissues were then incubated with a biotinylated horse antimouse secondary antibody (Vector Labs, Burlingame, Calif.), and reactivity was visualized with an avidin-biotin-immunoperoxidase system (Vector) using diaminobenzidine (0.03 percent) as the chromogen and hematoxylin as the counterstain. Samples of bladder carcinoma with known p53 mutations and documented accumulations of p53 protein by immunohistochemical analysis were used as positive controls. Normal urothelium and nonepithelial cells (lymphocytes, stromal cells, and endothelial cells), used as internal negative controls, demonstrated no immunoreactivity. Only nuclear localization of immunoreactivity was evaluated. The extent of nuclear reactivity was classified in four categories: no nuclear reactivity; a few focally positive nuclei (1 to 9 percent of tumor cells); heterogeneous nuclear reactivity (10 to 49 percent of tumor cells); and intense homogeneous nuclear reactivity (50 to 100 percent of tumor cells) (Figure 1Figure 1Immunohistochemical Detection of p53 Protein in the Nuclei of Transitional-Cell Carcinomas of the Bladder with the Anti-p53 Monoclonal Antibody PAb1801.). Only samples demonstrating at least 10 percent nuclear reactivity were considered to be p53-positive (to have an alteration in p53). We based this criterion on our demonstration of a strong correlation of mutations in the p53 gene with the accumulation of p53 protein in 10 percent or more of the tumor-cell nuclei5. The immunohistochemical analysis was performed without knowledge of the tumor stage or the results of clinical follow-up.

Statistical Analysis

Survival was calculated from cystectomy to the date of death or the date of the last follow-up (either a clinical visit or a discussion with the patient's referring physician); deaths due to any cause were considered to represent treatment failures. Time to recurrence was calculated from cystectomy to the date of the first documented clinical recurrence or the last follow-up; data on patients who died free of disease before any recurrence were censored at the time of death. One patient was known to have died of disease, but the date of recurrence was unknown and therefore a date midway between the last clinic visit and the date of death was used. For the purpose of the statistical analysis, nuclear accumulations of p53 were classified as either positive (accumulation in 10 percent or more of tumor cells) or negative.

Contingency tables, Pearson's chi-square test, and logistic regression17 were used to evaluate the association of p53 accumulation with lymph-node status, pathological stage of the primary tumor, and histologic grade. Kaplan-Meier plots18 and the log-rank test19 were used to evaluate the association of these three standard clinical prognostic variables, as well as the expression of p53, with the time to recurrence and with survival. Greenwood's formula19 was used to estimate the standard errors of the Kaplan-Meier estimates of the probability of survival or recurrence. To determine whether an accumulation of p53 provided prognostic information beyond that provided by the three standard clinical variables, a stratified log-rank test was used. All P values reported are two-sided.

The statistical analyses were performed for the entire cohort of 243 patients and were performed separately for the 190 patients not previously tested for accumulation of p53.

Results

Of the 190 bladder tumors not previously examined for accumulation of p53, 112 had no nuclear reactivity and 7 had a few focally positive tumor nuclei but less than 10 percent. These 119 tumors were considered p53-negative. In 54 of the remaining 71 tumors, p53 protein was detected in 10 to 49 percent of tumor-cell nuclei, and in 17 tumors p53 was seen in 50 to 100 percent of tumor-cell nuclei. These 71 bladder cancers were considered p53-positive. In all 243 patients, 142 tumors were classified as p53-negative and 101 as p53-positive.

Association of p53 Nuclear Reactivity with Tumor Grade, Pathological Stage, and Lymph-Node Status

Analysis of the 190 tumors not previously tested for p53 revealed that nuclear p53 was identified more frequently in grade 4 tumors than in grade 2 or 3 tumors, but this association was not statistically significant (P = 0.20) (Table 1Table 1Association of p53 Immunoreactivity with Grade and Pathological Stage of Bladder Cancer and Presence or Absence of Lymph-Node Metastases in 190 Patients Not Previously Tested for p53 Alterations.). By contrast, the presence of nuclear p53 was significantly associated with pathological stage (P = 0.003); 32 percent of the patients with negative lymph nodes, as compared with 55 percent of the patients with positive lymph nodes, had nuclear accumulation of p53 (P = 0.008). In patients with no evidence of lymph-node metastases, the presence of nuclear p53 was associated with greater depth of invasion; 22 percent of the patients with superficial disease (stage Pa, Pis, or P1), as compared with 38 percent of the patients with disease invasive of muscle (stages P2 through P4), had nuclear p53 in the tumor cells (P = 0.044). Similar results were obtained for the entire cohort of 243 patients.

Association of p53 Immunoreactivity with Recurrence and Overall Survival

In the group of 190 patients not previously tested for p53 alterations, nuclear accumulation of p53 was significantly associated with an increased probability of tumor recurrence (P<0.001) and a decreased probability of survival (P<0.001). Identical results were obtained for the entire cohort of 243 patients; Figure 2Figure 2Probability of Remaining Relapse-free in 243 Patients with Bladder Cancer and either p53-Positive or p53-Negative Tumors. and Figure 3Figure 3Probability of Survival in Patients with Bladder Cancer and either p53-Positive or p53-Negative Tumors. show curves for recurrence and survival for all patients.

Among the patients with no evidence of lymph-node involvement, nuclear accumulation of p53 was significantly associated with recurrence in those with disease confined to the bladder (stage P1, P2, or P3a). However, this association was not statistically significant among the patients with extravesical extension of tumor (stage P3b or P4) (Table 2Table 2Estimated Rates of Recurrence and Survival at Five Years in 190 Patients with Bladder Cancer, According to p53 Status of Tumors and Pathological Stage.). The five-year recurrence rates for patients with stage P1, P2, and P3a tumors that were p53-negative were 7, 12, and 11 percent, respectively. In contrast, the five-year recurrence rates were 62, 56, and 80 percent for stage P1, P2, and P3a tumors that were p53-positive (Table 2). In all subgroups of tumors confined to the bladder, the recurrence rates at five years for p53-negative and p53-positive tumors differed significantly. Significant differences in estimated five-year survival rates were also found among patients with tumors confined to the bladder (except stage P3a tumors) (Table 2). Identical results were obtained for the entire cohort of 243 patients. Figure 4Figure 4Probability of Remaining Relapse-free According to Pathological Stage in Patients with Organ-Confined Bladder Cancer but No Regional Lymph-Node Metastases. and Figure 5Figure 5Probability of Survival According to Pathological Stage in Patients with Organ-Confined Bladder Cancer but No Regional Lymph-Node Metastases. show the Kaplan-Meier curves for recurrence and survival in all 243 patients, stratified according to the depth of tumor invasion.

In a multivariable analysis stratified according to grade, pathological stage, and presence or absence of lymph-node metastases nuclear p53 status was an independent predictor of the recurrence of bladder cancer and of overall survival (P<0.001). When patients with lymph-node-negative cancers confined to the bladder were stratified according to p53 status, pathological stage (i.e., depth of invasion) was not an independent predictor of either recurrence (P = 0.62) or survival (P = 0.23).

Forty-one of the 243 patients received postoperative adjuvant systemic chemotherapy. When these patients were removed from the analysis, the presence of nuclear p53 remained highly associated with recurrence and death. This analysis demonstrates the predictive value of nuclear p53 reactivity in a cohort of patients uniformly treated with radical cystectomy and pelvic-lymph-node dissection but no adjuvant therapy.

Discussion

We found that the immunohistochemical detection of p53 protein in the nuclei of tumor cells can provide prognostic information in patients with bladder cancer. In patients with transitional-cell carcinoma of the bladder treated by cystectomy, the nuclear accumulation of p53 correlated with a significantly increased risk of recurrence and decreased overall survival. The link between nuclear p53 and prognosis was independent of tumor grade, pathological stage, and lymph-node status. The strongest association between p53 immunoreactivity in tumor-cell nuclei and tumor progression was observed when the disease was confined to the bladder. The presence of nuclear p53 was strongly associated with an increased risk of recurrence among patients with P1, P2, or P3a disease and with decreased overall survival among those with P1 or P2 disease. It was the only independent predictor of disease progression in a multivariable comparison of p53 status, pathological stage, and histologic grade.

The product of a mutated p53 gene can be a metabolically stable protein with a long half-life20. In contrast, wild-type p53 has a short half-life, only 6 to 30 minutes, and thus it does not generally accumulate in high enough levels to be detected by standard immunohistochemical methods. A long-lived mutated p53 protein, in contrast, is usually detectable by such techniques. We have previously demonstrated a significant association of p53 mutations with the immunohistochemical detection of p53 protein in tumor-cell nuclei5. Immunohistochemical techniques identified most cases in which the cells had mutated p53 genes, but 15 to 20 percent of tumors with demonstrable mutations of the p53 gene were negative by immunohistochemical analysis5. Moreover, a substantial proportion of tumors with nuclear accumulation of p53 lacked evidence of p53 gene mutation. Alterations that render the p53 protein detectable by immunohistochemical analysis may not require a mutation in the p53 gene. For example, cellular oncogene products that bind to and inactivate wild-type p53 protein, such as MDM2,21 may prolong the half-life of p53, allowing it to accumulate in the nucleus. Although this phenomenon has not been shown directly, recent studies indicate that cells that overexpress MDM2 can also overexpress p53 protein in the absence of a p53 gene mutation22. Moreover, the level of wild-type p53 protein can increase in response to DNA damage23. Thus, increases in the level of the p53 protein and mutation of the p53 gene occur together in most cases but can be separate events. Although we have shown that the presence of p53 alterations as detected by immunohistochemical methods is clinically relevant, it may also be important to assess mutations of the p53 gene directly as a prognostic indicator in bladder cancer.

The most important finding of this study is that in patients with transitional-cell carcinoma confined to the bladder (stages P1, P2, and P3a), and no evidence of lymph-node metastases, p53 nuclear reactivity identifies tumors with a tendency to progress. In these cases, the detection of nuclear p53 is more strongly associated with tumor recurrence and decreased survival than is the depth of invasion or histologic grade. Patients with p53-negative tumors had relatively low rates of recurrence, whereas metastases developed in the majority of patients with p53-positive tumors, regardless of depth of invasion. Although depth of invasion is clearly associated with the progression of disease in patients with bladder cancer, this may reflect the proportion of tumors in each stage that have p53 alterations.

This study may influence the selection of patients for adjuvant treatment of bladder cancer, which currently depends on the depth of tumor invasion and the detection of regional lymph-node metastases. The results of two recent studies are encouraging,11,12 but the role of adjuvant chemotherapy after cystectomy, particularly in patients with disease confined to the bladder, remains unresolved. Patients with p53-negative tumors confined to the bladder have a low rate of disease progression (even when there is deep muscle invasion) and may not require adjuvant treatment after radical cystectomy. In contrast, patients with p53-positive cancer confined to the bladder (including those with only superficially invasive tumors) have a poor prognosis. They may benefit from adjuvant treatment. This study and the study by Sarkis et al.13 are also relevant to the controversial issue of surgical treatment of superficially invasive bladder cancer. Patients with superficially invasive p53-positive tumors have a high rate of disease progression and may therefore benefit from early radical cystectomy. Moreover, our study indicates that patients with p53-positive tumors are at high risk of progression despite radical cystectomy and may therefore benefit from adjuvant treatment. Thus, the immunohistochemical detection of p53 may identify patients with cancer confined to the bladder who could benefit from radical surgery and adjuvant therapy. Furthermore, the absence of detectable p53 may be an indication for conservative therapy, even in the presence of locally advanced disease.

Supported in part by grants (R35 CA49758 and P30 CA14089) from the National Cancer Institute, by the American Foundation for Urologic Disease-National Kidney Foundation Fellowship, and by the Firestein-Gertz Cancer Research Fund.

We are indebted to Drs. Gary Lieskovsky and Stuart Boyd for providing some of the patients included in this study, and to Drs. Ron Natale and Clive Taylor for their critical review of this work.

Source Information

From the Departments of Urology (D. Esrig, D. Elmajian, J.A.F., J.P.S., D.G.S., P.A.J.), Preventive Medicine (S.G., S.-C.C.), and Pathology (P.W.N., R.J.C.), University of Southern California School of Medicine and Kenneth Norris Jr. Comprehensive Cancer Center, Los Angeles.

Address reprint requests to Dr. Cote at the Department of Pathology, University of Southern California School of Medicine, Kenneth Norris Jr. Cancer Center, 1441 Eastlake Ave., Los Angeles, CA 90033.

References

References

1. 1

   Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science 1991;253:49-53
   CrossRef | Web of Science | Medline

2. 2

   Lane DP. Cancer: p53, guardian of the genome. Nature 1992;358:15-16
   CrossRef | Web of Science | Medline

3. 3

   Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991;252:706-709
   CrossRef | Web of Science | Medline

4. 4

   Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-788
   Web of Science | Medline

5. 5

   Esrig D, Spruck CH III, Nichols PW, et al. p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397
   Web of Science | Medline

6. 6

   Sarkis AS, Zhang Z, Cordon-Cardo C, et al. p53 Nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol 1993;3:355-360
   Web of Science | Medline

7. 7

   Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer: oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am 1992;19:629-639
   Web of Science | Medline

8. 8

   Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-1256
   CrossRef | Web of Science | Medline

9. 9

   Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-1261
   CrossRef | Web of Science | Medline

10. 10

    Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982;128:34-36
    Web of Science | Medline

11. 11

    Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459-467
    Web of Science | Medline

12. 12

    Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy: results of a controlled prospective study. J Urol 1992;148:302-307
    Web of Science | Medline

13. 13

    Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-59
    CrossRef | Web of Science | Medline

14. 14

    Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365-370
    CrossRef | Web of Science | Medline

15. 15

    Bergkvist A, Ljungqvist A, Moberger G. Classification of bladder tumours based on the cellular pattern. Acta Chir Scand 1965;130:371-378
    Medline

16. 16

    Hermanek P, Sobin LH, eds. TNM classification of malignant tumors. 4th ed. New York: Springer-Verlag, 1987:133-4.
    

17. 17

    Fienberg SE. The analysis of cross-classified categorical data. Cambridge, Mass.: MIT Press, 1977:9-86.
    

18. 18

    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
    CrossRef | Web of Science

19. 19

    Miller RG Jr. Survival analysis. New York: John Wiley, 1981:44-102.
    

20. 20

    Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine MJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539
    Web of Science | Medline

21. 21

    Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83
    CrossRef | Web of Science | Medline

22. 22

    Cordon-Cardo C, Latres E, Drobjnak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-799
    Web of Science | Medline

23. 23

    Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311
    Web of Science | Medline

Citing Articles (319)

Citing Articles

1. 1

   Georgios Gakis, Christian Schwentner, Tilman Todenhoefer, Arnulf Stenzl. (2012) Current status of molecular markers for prognostication and outcome in invasive bladder cancer. BJU Internationalno-no
   CrossRef

2. 2

   Thomas W. Flaig, Dan Theodorescu. (2011) Bladder cancer in 2011: The dawn of personalized medicine. Nature Reviews Urology
   CrossRef

3. 3

   Kevin R. Loughlin. (2011) Bladder cancer: A window of opportunity to understand carcinogenesis. Urologic Oncology: Seminars and Original Investigations
   CrossRef

4. 4

   Shahrokh F. Shariat, Thomas F. Chromecki, Eugene K. Cha, Pierre I. Karakiewicz, Maxine Sun, Yves Fradet, Hendrik Isbarn, Douglas S. Scherr, Patrick J. Bastian, Karl Pummer, Harun Fajkovic, Arthur I. Sagalowsky, Raheela Ashfaq, Matthias Doblinger, Richard J. Cote, Yair Lotan. (2011) Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. The Journal of Urology
   CrossRef

5. 5

   Serpil Oğuztüzün, Yasemin Sezgin, Sertaç Yazıcı, Pınar Fırat, Müzeyyen Özhavzalı, Haluk Özen. (2011) Expression of glutathione-S-transferases isoenzymes and p53 in exfoliated human bladder cancer cells. Urologic Oncology: Seminars and Original Investigations 29:5, 538-544
   CrossRef

6. 6

   Afrodite Athanasopoulou, Panagiotis Aroukatos, Dimitrios Nakas, Maria Repanti, Helen Papadaki, Vasiliki Bravou. (2011) Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression. Urologic Oncology: Seminars and Original Investigations
   CrossRef

7. 7

   Anirban P. Mitra, David I. Quinn, Tanya B. Dorff, Eila C. Skinner, Anne K. Schuckman, Gus Miranda, Inderbir S. Gill, Siamak Daneshmand. (2011) Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Internationalno-no
   CrossRef

8. 8

   M. Burger, F. Dorp. (2011) Nutzung von Markersystemen in der Behandlung des Harnblasenkarzinoms. Der Urologe 50:3, 303-308
   CrossRef

9. 9

   Usha Agrawal, Ashwani K. Mishra, Payal Salgia, Saurabh Verma, Nayan K. Mohanty, Sunita Saxena. (2011) Role of Tumor Suppressor and Angiogenesis Markers in Prediction of Recurrence of Non Muscle Invasive Bladder Cancer. Pathology & Oncology Research 17:1, 91-101
   CrossRef

10. 10

    Hervé Wallerand, Jean-Christophe Bernhard, Stéphane Culine, Philippe Ballanger, Grégoire Robert, Robert E. Reiter, Jean-Marie Ferrière, Alain Ravaud. (2011) Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urologic Oncology: Seminars and Original Investigations 29:1, 4-11
    CrossRef

11. 11

    Zhi-Long Dong, Ze-Ping Lu, Han-Zhang Wang, Li-Yuan Zhang, Zhi-Ping Wang, Yu-Fang Zhang, Bao-Liang Ma. (2011) Detection of Nuclear Matrix Protein 22 and Survivin Baseline Level in Patients after Radical Cystectomy. Urologia Internationalis 87:4, 445-449
    CrossRef

12. 12

    Zana Dolicanin, Ljubinka Jankovic-Velickovic, Biljana Djordjevic, Milan Visnjic, Ivana Pesic, Ana Ristic, Vesna Marjanovic. (2011) Expression of regulatory proteins and proliferative activity in relation to phenotypic characteristics of upper urothelial carcinoma. Vojnosanitetski pregled 68:7, 567-574
    CrossRef

13. 13

    Lauren C. Harshman, Gerold Bepler, Zhong Zheng, John P. Higgins, Genevera I. Allen, Sandy Srinivas. (2010) Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU International 106:11, 1805-1811
    CrossRef

14. 14

    Georg Bartsch, Anirban P Mitra, Richard J Cote. (2010) Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Review of Anticancer Therapy 10:12, 1945-1954
    CrossRef

15. 15

    Matthew D. Galsky, Simon J. Hall. (2010) Bladder Cancer: Current Management and Opportunities for a Personalized Approach. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, 587-596
    CrossRef

16. 16

    A. Font, M. Taron, J. L. Gago, C. Costa, J. J. Sanchez, C. Carrato, M. Mora, P. Celiz, L. Perez, D. Rodriguez, A. Gimenez-Capitan, V. Quiroga, S. Benlloch, L. Ibarz, R. Rosell. (2010) BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Annals of Oncology
    CrossRef

17. 17

    Jin Yang, Zhigang Xu, Jie Li, Rong Zhang, Guizheng Zhang, Huixiang Ji, Bo Song, Zhiwen Chen. (2010) XPC Epigenetic Silence Coupled With p53 Alteration Has a Significant Impact on Bladder Cancer Outcome. The Journal of Urology 184:1, 336-343
    CrossRef

18. 18

    Ian Proctor, Kai Stoeber, Gareth H Williams. (2010) Biomarkers in bladder cancer. Histopathology 57:1, 1-13
    CrossRef

19. 19

    David J. McConkey, Sangkyou Lee, Woonyoung Choi, Mai Tran, Tadeusz Majewski, Sooyong Lee, Arlene Siefker-Radtke, Colin Dinney, Bogdan Czerniak. (2010) Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic Oncology: Seminars and Original Investigations 28:4, 429-440
    CrossRef

20. 20

    Thorsten H. Ecke. (2010) Tumor markers for bladder cancer: outlook for routine use ¹. LaboratoriumsMedizin 34:2, ---
    CrossRef

21. 21

    Thorsten H. Ecke. (2010) Tumormarker beim Blasentumor: Aussichten für den klinischen Alltag / Tumor markers for bladder cancer: outlook for routine use. LaboratoriumsMedizin 34:2, 77-86
    CrossRef

22. 22

    Shahrokh F. Shariat, Christian Bolenz, Pierre I. Karakiewicz, Yves Fradet, Raheela Ashfaq, Patrick J. Bastian, Matthew E. Nielsen, Umberto Capitanio, Claudio Jeldres, Jérôme Rigaud, Stefan C. Müller, Seth P. Lerner, Francesco Montorsi, Arthur I. Sagalowsky, Richard J. Cote, Yair Lotan. (2010) p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU International 105:4, 489-495
    CrossRef

23. 23

    M. Ishida, S. Mikami, E. Kikuchi, T. Kosaka, A. Miyajima, K. Nakagawa, M. Mukai, Y. Okada, M. Oya. (2010) Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31:2, 287-295
    CrossRef

24. 24

    Shahrokh F. Shariat, Daher C. Chade, Pierre I. Karakiewicz, Raheela Ashfaq, Hendrik Isbarn, Yves Fradet, Patrick J. Bastian, Matthew E. Nielsen, Umberto Capitanio, Claudio Jeldres, Francesco Montorsi, Seth P. Lerner, Arthur I. Sagalowsky, Richard J. Cote, Yair Lotan. (2010) Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. The Journal of Urology 183:1, 68-75
    CrossRef

25. 25

    Yair Lotan. (2010) Role of biomarkers to predict outcomes and response to therapy. Urologic Oncology: Seminars and Original Investigations 28:1, 97-101
    CrossRef

26. 26

    Carlos Lojo Rial, Daniel Wilby, Prasanna Sooriakumaran. (2009) Role and rationale of gene therapy and other novel therapies in the management of NMIBC. Expert Review of Anticancer Therapy 9:12, 1777-1782
    CrossRef

27. 27

    Andrew J. Vickers, Angel M. Cronin, Michael W. Kattan, Mithat Gonen, Peter T. Scardino, Matthew I. Milowsky, Guido Dalbagni, Bernard H. Bochner, . (2009) Clinical benefits of a multivariate prediction model for bladder cancer. Cancer 115:23, 5460-5469
    CrossRef

28. 28

    Anirban P. Mitra, Claudia C. Bartsch, Richard J. Cote. (2009) Strategies for molecular expression profiling in bladder cancer. Cancer and Metastasis Reviews 28:3-4, 317-326
    CrossRef

29. 29

    Shahrokh F. Shariat, Matthew Milowsky, Michael J. Droller. (2009) Bladder cancer in the elderly. Urologic Oncology: Seminars and Original Investigations 27:6, 653-667
    CrossRef

30. 30

    Elke Eltze, Peter J. Wild, Christian Wülfing, Ellen C. Zwarthoff, Maximilian Burger, Robert Stoehr, Eberhard Korsching, Arndt Hartmann. (2009) Expression of the Endothelin Axis in Noninvasive and Superficially Invasive Bladder Cancer: Relation to Clinicopathologic and Molecular Prognostic Parameters. European Urology 56:5, 837-847
    CrossRef

31. 31

    Shahrokh F. Shariat, Yair Lotan, Pierre I. Karakiewicz, Raheela Ashfaq, Hendrik Isbarn, Yves Fradet, Patrick J. Bastian, Matthew E. Nielsen, Umberto Capitanio, Claudio Jeldres, Francesco Montorsi, Stefan C. Müller, Jose A. Karam, Lukas C. Heukamp, George Netto, Seth P. Lerner, Arthur I. Sagalowsky, Richard J. Cote. (2009) p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. The Journal of Urology 182:3, 907-913
    CrossRef

32. 32

    Shahrokh F. Shariat, Christian Bolenz, Guilherme Godoy, Yves Fradet, Raheela Ashfaq, Pierre I. Karakiewicz, Hendrik Isbarn, Claudio Jeldres, Jérôme Rigaud, Arthur I. Sagalowsky, Yair Lotan. (2009) Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. The Journal of Urology 182:1, 78-84
    CrossRef

33. 33

    Peter E Clark. (2009) Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 9:6, 821-830
    CrossRef

34. 34

    Ofer N. Gofrit, Dov Pode, Galina Pizov, Kevin C. Zorn, Ran Katz, Mordechi Duvdevani, Amos Shapiro. (2009) The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy. Urologic Oncology: Seminars and Original Investigations 27:3, 258-262
    CrossRef

35. 35

    Bernard H. Bochner. (2009) Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations 27:3, 329-331
    CrossRef

36. 36

    J. Bellmunt, S. Albiol, C. Suárez, J. Albanell. (2009) Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Critical Reviews in Oncology/Hematology 69:3, 211-222
    CrossRef

37. 37

    Joshua F. Coleman, Donna E. Hansel. (2009) Utility of Diagnostic and Prognostic Markers in Urothelial Carcinoma of the Bladder. Advances in Anatomic Pathology 16:2, 67-78
    CrossRef

38. 38

    Anirban P. Mitra, Richard J. Cote. (2009) Molecular Pathogenesis and Diagnostics of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease 4:1, 251-285
    CrossRef

39. 39

    Ramy F. Youssef, Anirban P. Mitra, Georg Bartsch, Peter A. Jones, Donald G. Skinner, Richard J. Cote. (2009) Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology 27:1, 9-20
    CrossRef

40. 40

    DEBRA HAWES, SHAN-RONG SHI, DAVID J. DABBS, CLIVE R. TAYLOR, RICHARD J. COTE. 2009. Immunohistochemistry. , 48-70.
    CrossRef

41. 41

    RICHARD J. COTE, ANIRBAN P. MITRA, MAHUL B. AMIN. 2009. Bladder and Urethra. , 1079-1120.
    CrossRef

42. 42

    S. Joseph Sirintrapun, Anil V. Parwani. (2008) Molecular Pathology of the Genitourinary Tract: Prostate and Bladder. Surgical Pathology Clinics 1:1, 211-236
    CrossRef

43. 43

    Christian Bolenz, Yair Lotan. (2008) Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nature Clinical Practice Urology 5:12, 676-685
    CrossRef

44. 44

    Antonio S. Salinas-Sánchez, Juan G. Lorenzo-Romero, José M. Giménez-Bachs, Francisco Sánchez-Sánchez, María J. Donate-Moreno, Antonio Rubio-del-Campo, Ibrahim R. Hernández-Millán, Miguel Segura-Martín, Manuel Atienzar-Tobarra, Julio Escribano-Martínez. (2008) Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: A long-term study. Urologic Oncology: Seminars and Original Investigations 26:6, 620-626
    CrossRef

45. 45

    Hiroyuki Nishiyama, Jun Watanabe, Osamu Ogawa. (2008) p53 and chemosensitivity in bladder cancer. International Journal of Clinical Oncology 13:4, 282-286
    CrossRef

46. 46

    Guru Sonpavde, Gilad E Amiel, Martha P Mims, Teresa G Hayes, Seth P Lerner. (2008) Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opinion on Pharmacotherapy 9:11, 1885-1893
    CrossRef

47. 47

    Vitaly Margulis, Yair Lotan, Francesco Montorsi, Shahrokh F. Shariat. (2008) Predicting survival after radical cystectomy for bladder cancer. BJU International 102:1, 15-22
    CrossRef

48. 48

    Tadeusz Majewski, Sangkyou Lee, Joon Jeong, Dong-Sup Yoon, Andrzej Kram, Mi-Sook Kim, Tomasz Tuziak, Jolanta Bondaruk, Sooyong Lee, Weon-Seo Park, Kuang S Tang, Woonbok Chung, Lanlan Shen, Saira S Ahmed, Dennis A Johnston, H Barton Grossman, Colin P Dinney, Jain-Hua Zhou, R Alan Harris, Carrie Snyder, Slawomir Filipek, Steven A Narod, Patrice Watson, Henry T Lynch, Adi Gazdar, Menashe Bar-Eli, Xifeng F Wu, David J McConkey, Keith Baggerly, Jean-Pierre Issa, William F Benedict, Steven E Scherer, Bogdan Czerniak. (2008) Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Laboratory Investigation 88:7, 694-721
    CrossRef

49. 49

    Franck Bruyere, Niall M. Corcoran, Navid Berdjis, Benjamin Namdarian, John Pedersen, Jeremy Ockrim, Bryan B. Voelzke, Anthony J. Costello, Christopher M. Hovens. (2008) Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint. BJU International 102:2, 247-252
    CrossRef

50. 50

    Behfar Ehdaie, Dan Theodorescu. (2008) Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Review of Anticancer Therapy 8:7, 1103-1110
    CrossRef

51. 51

    Andreas Hinkel, Sonja Schmidtchen, Rein-Jueri Palisaar, Joachim Noldus, Jürgen Pannek. (2008) Identification of Bladder Cancer Patients at Risk for Recurrence or Progression: An Immunohistochemical Study Based on the Expression of Metallothionein. Journal of Toxicology and Environmental Health, Part A 71:13-14, 954-959
    CrossRef

52. 52

    Daniel Y. C. Heng, Jorge A. Garcia. (2008) High-risk bladder cancer: improving outcomes with perioperative chemotherapy. Oncology Reviews 2:1, 4-8
    CrossRef

53. 53

    Shahrokh F. Shariat, Pierre I. Karakiewicz, Raheela Ashfaq, Seth P. Lerner, Ganesh S. Palapattu, Richard J. Cote, Arthur I. Sagalowsky, Yair Lotan. (2008) Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112:2, 315-325
    CrossRef

54. 54

    Kyung Seok Han, In Gab Jeong, Jae Young Joung, Seung Ok Yang, Jinsoo Chung, Ho Kyung Seo, Kyung Suk Kwon, Weon Seo Park, Kang Hyun Lee. (2008) Clinical Value of PTEN in Patients with Superficial Bladder Cancer. Urologia Internationalis 80:3, 264-269
    CrossRef

55. 55

    Shahrokh F Shariat, Jose A Karam, Seth P Lerner. (2008) Molecular markers in bladder cancer. Current Opinion in Urology 18:1, 1-8
    CrossRef

56. 56

    Karim Bensalah, Francesco Montorsi, Shahrokh F. Shariat. (2007) Challenges of Cancer Biomarker Profiling. European Urology 52:6, 1601-1609
    CrossRef

57. 57

    Marc Birkhahn, Anirban P Mitra, Richard J Cote. (2007) Molecular markers for bladder cancer: the road to a multimarker approach. Expert Review of Anticancer Therapy 7:12, 1717-1727
    CrossRef

58. 58

    E. Andrés Houseman, Carmen Marsit, Margaret Karagas, Louise M. Ryan. (2007) Penalized Item Response Theory Models: Application to Epigenetic Alterations in Bladder Cancer. Biometrics 63:4, 1269-1277
    CrossRef

59. 59

    Anirban P. Mitra, Marc Birkhahn, Richard J. Cote. (2007) p53 and retinoblastoma pathways in bladder cancer. World Journal of Urology 25:6, 563-571
    CrossRef

60. 60

    Johanna M.M. van Oers, Peter J. Wild, Maximilian Burger, Stefan Denzinger, Robert Stoehr, Elke Rosskopf, Ferdinand Hofstaedter, Ewout W. Steyerberg, Monika Klinkhammer-Schalke, Ellen C. Zwarthoff, Theodorus H. van der Kwast, Arndt Hartmann. (2007) FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. European Urology 52:3, 760-768
    CrossRef

61. 61

    M. May, K.-P. Braun, W. Richter, C. Helke, H. Vogler, B. Hoschke, M. Siegsmund. (2007) Stellen wir die Indikation zur radikalen Zystektomie immer zeitgerecht?. Der Urologe 46:8, 913-919
    CrossRef

62. 62

    Jung-Ta Kao, Seng-Kee Chuah, Chao-Cheng Huang, Chao-Long Chen, Chih-Chi Wang, Chao-Hung Hung, Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu, Chuan-Mo Lee, Chi-Sin Changchien, Tsung-Hui Hu. (2007) P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. Liver International 27:6, 772-781
    CrossRef

63. 63

    William M. Murphy. (2007) Anatomical pathology in the 21st century—the great paradigm shift. Human Pathology 38:7, 957-962
    CrossRef

64. 64

    Seth P. Lerner, Bernard Bochner, Adam S. Kibel. (2007) The use and abuse of data: Nomograms and talking to patients about clinical medicine. Urologic Oncology: Seminars and Original Investigations 25:4, 333-337
    CrossRef

65. 65

    Yao-Yuan Hsieh, Jui-Ping Wang, Chich-Sheng Lin. (2007) Four novel single nucleotide polymorphisms within the promoter region of p53 gene and their associations with uterine leiomyoma. Molecular Reproduction and Development 74:7, 815-820
    CrossRef

66. 66

    Jorunn Litlekalsoy, Vendil Vatne, Jens G. Hostmark, Ole Didrik Laerum. (2007) Immunohistochemical markers in urinary bladder carcinomas from paraffin-embedded archival tissue after storage for 5?70years. BJU International 99:5, 1013-1019
    CrossRef

67. 67

    Mark L. Gonzalgo, Ram H. Datar, Mark P. Schoenberg, Richard J. Cote. (2007) The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations 25:3, 228-235
    CrossRef

68. 68

    Joaquim Bellmunt, Santiago Albiol. (2007) Chemotherapy for Metastatic or Unresectable Bladder Cancer. Seminars in Oncology 34:2, 135-144
    CrossRef

69. 69

    Shahrokh F Shariat, Alexandre R Zlotta, Raheela Ashfaq, Arthur I Sagalowsky, Yair Lotan. (2007) Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Modern Pathology 20:4, 445-459
    CrossRef

70. 70

    Jose A Karam, Yair Lotan, Pierre I Karakiewicz, Raheela Ashfaq, Arthur I Sagalowsky, Claus G Roehrborn, Shahrokh F Shariat. (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. The Lancet Oncology 8:2, 128-136
    CrossRef

71. 71

    Danish Mazhar, Nasim Ali, Sarah Ngan. (2007) Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?. Future Oncology 3:1, 5-8
    CrossRef

72. 72

    Kayoko YONEMARU, Hiroki SAKAI, Mami MURAKAMI, Atsushi KODAMA, Takashi MORI, Tokuma YANAI, Kohji MARUO, Toshiaki MASEGI. (2007) The Significance of p53 and Retinoblastoma Pathways in Canine Hemangiosarcoma. Journal of Veterinary Medical Science 69:3, 271-278
    CrossRef

73. 73

    S. Bruce Malkowicz, Hendrik van Poppel, Gerald Mickisch, Vito Pansadoro, Joachim Thüroff, Mark S. Soloway, Sam Chang, Mitchell Benson, Iwao Fukui. (2007) Muscle-Invasive Urothelial Carcinoma of the Bladder. Urology 69:1, 3-16
    CrossRef

74. 74

    Won Sik Ham, Joo Hyoung Lee, Ho Song Yu, Young Deuk Choi. (2007) Analysis of Human V-erbA Related EAR-3 Gene Expression between Transitional Cell Carcinoma and Normal Tissue in Bladder Cancer. Korean Journal of Urology 48:9, 915
    CrossRef

75. 75

    Kokichi Sugano, Tadao Kakizoe. (2006) Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nature Clinical Practice Urology 3:12, 642-652
    CrossRef

76. 76

    Ahmad Shabsigh, Bernard H. Bochner. (2006) Use of nomograms as predictive tools in bladder cancer. World Journal of Urology 24:5, 489-498
    CrossRef

77. 77

    Christopher Y. Thomas, Dan Theodorescu. (2006) Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology 24:5, 565-578
    CrossRef

78. 78

    Fabia Galmozzi, Alessandra Rubagotti, Andrea Romagnoli, Giorgio Carmignani, Luisa Perdelli, Beatrice Gatteschi, Francesco Boccardo. (2006) Prognostic value of cell cycle regulatory proteins in muscle-infiltrating bladder cancer. Journal of Cancer Research and Clinical Oncology 132:12, 757-764
    CrossRef

79. 79

    Aude Flechon, Jean-Pierre Droz. (2006) Chemotherapy practices and perspectives in invasive bladder cancer. Expert Review of Anticancer Therapy 6:10, 1473-1482
    CrossRef

80. 80

    Andriy O. Yurakh, David Ramos, Silvia Calabuig-Fariñas, José Antonio López-Guerrero, José Rubio, Eduardo Solsona, Alina M. Romanenko, Alexander F. Vozianov, Antonio Pellin, Antonio Llombart-Bosch. (2006) Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder. European Urology 50:3, 506-515
    CrossRef

81. 81

    Ömer Gülpinar, Tarkan Soygür, Sümer Baltaci, Murat Akand, Duygu Kankaya. (2006) Transitional cell carcinoma of bladder with lamina propria invasion in a 10-year-old boy. Urology 68:1, 204.e1-204.e3
    CrossRef

82. 82

    D Dhawan, FC Hamdy, I Rehman, J Patterson, SS Cross, KM Feeley, Y Stephenson, M Meuth, JWF Catto. (2006) Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. The Journal of Pathology 209:3, 336-343
    CrossRef

83. 83

    Shin Egawa, Hidetoshi Kuruma. (2006) Search for Biomarkers of Aggressiveness in Bladder Cancer. European Urology 50:1, 20-22
    CrossRef

84. 84

    Stavros Touloupidis, Georgios Fatles, Christos Kalaitzis, Alexandra Giatromanolaki, Eythimyos Sivridis, Konstantinos Simopoulos, Vassilios Rombis. (2006) The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. International Urology and Nephrology 38:2, 231-236
    CrossRef

85. 85

    Iman J. Schultz, J. Alfred Witjes, Dorine W. Swinkels, Jacques B. de Kok. (2006) Bladder cancer diagnosis and recurrence prognosis: Comparison of markers with emphasis on survivin. Clinica Chimica Acta 368:1-2, 20-32
    CrossRef

86. 86

    Colin P.N. Dinney. (2006) Therapy of invasive bladder cancer. Urology 67:3, 56-59
    CrossRef

87. 87

    A Irie, K Matsumoto, B Anderegg, H Kuruma, M Kashani-Sabet, K J Scanlon, T Uchida, S Baba. (2006) Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. Cancer Gene Therapy 13:3, 298-305
    CrossRef

88. 88

    G Xia, S R Kumar, J P Stein, J Singh, V Krasnoperov, S Zhu, L Hassanieh, D L Smith, M Buscarini, D Broek, D I Quinn, F A Weaver, P S Gill. (2006) EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene 25:5, 769-780
    CrossRef

89. 89

    Gilad E Amiel, Seth P Lerner. (2006) Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Review of Anticancer Therapy 6:2, 281-291
    CrossRef

90. 90

    James W.F. Catto, Maysam F. Abbod, Derek A. Linkens, Freddie C. Hamdy. (2006) Neuro-Fuzzy Modeling: An Accurate and Interpretable Method for Predicting Bladder Cancer Progression. The Journal of Urology 175:2, 474-479
    CrossRef

91. 91

    Stefan Krüger, Anne Mahnken, Ingo Kausch, Alfred C. Feller. (2006) Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 67:1, 105-109
    CrossRef

92. 92

    Camillo F Pollera, Fabrizio Nelli. (2006) Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Expert Review of Anticancer Therapy 6:1, 83-92
    CrossRef

93. 93

    Toshiko Takahashi, Shigeru Hagisawa, Kazuyuki Yoshikawa, Fumiaki Tezuka, Mitsuo Kaku, Chikara Ohyama. (2006) Predictive Value of N-Acetylglucosaminyltransferase-V for Superficial Bladder Cancer Recurrence. The Journal of Urology 175:1, 90-93
    CrossRef

94. 94

    Yoshiaki Yamamoto, Hideyasu Matsuyama, Shigeto Kawauchi, Hiroaki Matsumoto, Kazuhiro Nagao, Chietaka Ohmi, Shigeru Sakano, Tomoko Furuya, Atsunori Oga, Katsusuke Naito, Kohsuke Sasaki. (2006) Overexpression of Polo-Like Kinase 1 (PLK1) and Chromosomal Instability in Bladder Cancer. Oncology 70:3, 231-237
    CrossRef

95. 95

    Enver Vardar, Bulent Gunlusoy, S&uuml;leyman Minareci, Hakan Postaci, Ali Riza Ayder. (2006) Evaluation of p53 Nuclear Accumulation in Low- and High-Grade (WHO/ISUP Classification) Transitional Papillary Carcinomas of the Bladder for Tumor Recurrence and Progression. Urologia Internationalis 77:1, 27-33
    CrossRef

96. 96

    Xiang-hui Yue, Xiao-hong Yang, Fu-qing Zheng. (2005) Recurrence risk factors in patients with transitional cell carcinoma of bladder. Chinese Journal of Cancer Research 17:4, 278-282
    CrossRef

97. 97

    Tomonori Habuchi, Michael Marberger, Michael J. Droller, George P. Hemstreet, H. Barton Grossman, Jack A. Schalken, Bernd J. Schmitz-Dräger, William M. Murphy, Aldo V. Bono, Peter Goebell, Robert H. Getzenberg, Stefan H. Hautmann, Edward Messing, Yves Fradet, Vinata B. Lokeshwar. (2005) Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66:6, 64-74
    CrossRef

98. 98

    ROBERT L. GRUBB, ASHISH BEHARI, CHONG M. KIM, CHRISTOPHER R. WILLIAMS, W. MARSTON LINEHAN, JONATHAN A. COLEMAN. (2005) HIGHLIGHTS FROM THE SOCIETY OF UROLOGIC ONCOLOGY, 5TH ANNUAL MEETING, DECEMBER 3–4, 2004, BETHESDA, MARYLAND, UNITED STATES OF AMERICA. The Journal of Urology 174:6, 2330-2333
    CrossRef

99. 99

    Andreas Eisenhardt, Winfried Siffert, Dieter Rosskopf, Michael Musch, Max Mosters, Ulla Roggenbuck, Karl-Heinz Jöckel, Herbert Rübben, Gerd Lümmen. (2005) Association study of the G-protein β3 subunit C825T polymorphism with disease progression in patients with bladder cancer. World Journal of Urology 23:4, 279-286
    CrossRef

100. 100

     Karen Giselle Chee, Angelo Cambio, Primo N Lara. (2005) Recent developments in advanced urothelial cancer. Current Opinion in Urology 15:5, 342-349
     CrossRef

101. 101

     Xue-Ru Wu. (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nature Reviews Cancer 5:9, 713-725
     CrossRef

102. 102

     George J. Chiang, Brian R. Billmeyer, David Canes, John Stoffel, Alireza Moinzadeh, Christina A. Austin, Monika Kosakowski, Kimberly M. Rieger-Christ, John A. Libertino, Ian C. Summerhayes. (2005) The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. BJU International 96:3, 416-422
     CrossRef

103. 103

     Penelope Korkolopoulou, Nikolaos Givalos, Angelica Saetta, Athina Goudopoulou, Hariklia Gakiopoulou, Irene Thymara, Euphemia Thomas-Tsagli, Efstratios Patsouris. (2005) Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Human Pathology 36:8, 899-907
     CrossRef

104. 104

     MEE JOO, HANSEONG KIM, MIN KYUNG KIM, HANG JONG YU, JIN-POK KIM. (2005) Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. Journal of Gastroenterology and Hepatology 20:7, 1039-1045
     CrossRef

105. 105

     Anirban P. Mitra, Ram H. Datar, Richard J. Cote. (2005) Molecular staging of bladder cancer. BJU International 96:1, 7-12
     CrossRef

106. 106

     Michelle Boyar, Daniel P. Petrylak. (2005) Adjuvant chemotherapy for transitional cell carcinoma of the bladder: Paradigms for the design of clinical trials. Current Oncology Reports 7:3, 207-214
     CrossRef

107. 107

     Murugesan Manoharan, Mark S. Soloway. (2005) Optimal Management of the T1G3 Bladder Cancer. Urologic Clinics of North America 32:2, 133-145
     CrossRef

108. 108

     Ana M. Aparicio, Anthony B. Elkhouiery, David I. Quinn. (2005) The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. Urologic Clinics of North America 32:2, 217-230
     CrossRef

109. 109

     Maurizio Buscarini, Marcus L. Quek, Parkash Gill, Guangbin Xia, David I. Quinn, John P. Stein. (2005) Molecular prognostic factors in bladder cancer. BJU International 95:6, 739-742
     CrossRef

110. 110

     J MCKNIGHT, S GRAY, H OKANE, S JOHNSTON, K WILLIAMSON. (2005) APOPTOSIS AND CHEMOTHERAPY FOR BLADDER CANCER. The Journal of Urology 173:3, 683-690
     CrossRef

111. 111

     Mee Joo, Je G. Chi, Hyucksang Lee. (2005) Expressions of HSP70 and HSP27 in Hepatocellular Carcinoma. Journal of Korean Medical Science 20:5, 829
     CrossRef

112. 112

     Vibhav Malviya, Harbans Singh, U. S. Dwivedi, Usha, P. B. Singh. (2004) Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?. Urological Research 32:6, 391-394
     CrossRef

113. 113

     Stephen G. Williams, John P. Stein. (2004) Molecular pathways in bladder cancer. Urological Research 32:6, 373-385
     CrossRef

114. 114

     EYUP GUMUS, SIBEL ERDAMAR, GULDEREN DEMIREL, KAYA HORASANLI, MUAMMER KENDIRCI, CENGIZ MIROGLU. (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. International Journal of Urology 11:12, 1070-1077
     CrossRef

115. 115

     Konstantinos N. Syrigos, Eleni Karapanagiotou, Kevin J. Harrington. (2004) The Clinical Significance of Molecular Markers to Bladder Cancer. Hybridoma and Hybridomics 23:6, 335-342
     CrossRef

116. 116

     P. Soriano, S. Navarro, M. Gil, A. Llombart-Bosch. (2004) Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases. Virchows Archiv 445:3, 292-297
     CrossRef

117. 117

     Peter J Goebell, Susan Groshen, Bernd J Schmitz-Dräger, Richard Sylvester, Manolis Kogevinas, Núria Malats, Guido Sauter, H Barton Grossman, Fred Waldman, Richard J Cote. (2004) The International Bladder Cancer Bank: Proposal for a new study concept. Urologic Oncology: Seminars and Original Investigations 22:4, 277-284
     CrossRef

118. 118

     Yao-Yuan Hsieh, Chi-Chen Chang, Chih-Wei Hsu, Chich-Sheng Lin. (2004) Gene transfections with p53 and p21 inhibit cell proliferation, collagen type I, leukemia inhibitory factor, and tumor necrosis factor-α expression in leiomyoma cells. Fertility and Sterility 81:6, 1665-1670
     CrossRef

119. 119

     Jun Watanabe, Hiroyuki Nishiyama, Kazutoshi Okubo, Takeshi Takahashi, Yoshinobu Toda, Tomonori Habuchi, Yoshiyuki Kakehi, Mitsuhiro Tada, Osamu Ogawa. (2004) Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 63:5, 989-993
     CrossRef

120. 120

     Xavier Garcia del Muro, Enric Condom, Francesc Vigus, Xavier Castellsagu, Agns Figueras, Josep Muoz, Judit Sol, Teresa Soler, Gabriel Capell, Josep R. Germ. (2004) p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 100:9, 1859-1867
     CrossRef

121. 121

     Tzong-Shin Tzai, Yuh-Shyan Tsai, Nan-Haw Chow. (2004) The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations 22:2, 112-118
     CrossRef

122. 122

     X. Wu, T. Obata, Q. Khan, R.A. Highshaw, R. de Vere White, C. Sweeney. (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU International 93:1, 143-150
     CrossRef

123. 123

     Eyup Gumus, Sibel Erdamar, Gulderen Demirel, Kaya Horasanli, G&ouml;khan &Ouml;zmen, Cengiz Miroglu. (2004) Relation between Serum Anti-p53 Antibodies and Microvessel Density in Bladder Cancer Patients. Urologia Internationalis 73:3, 219-225
     CrossRef

124. 124

     Derek Raghavan. (2003) Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urologic Oncology: Seminars and Original Investigations 21:6, 468-474
     CrossRef

125. 125

     Lance C Pagliaro, Afsaneh Keyhani, Baoshun Liu, Paul Perrotte, Deborah Wilson, Colin P Dinney. (2003) Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urologic Oncology: Seminars and Original Investigations 21:6, 456-462
     CrossRef

126. 126

     Randall Millikan, Arlene Siefker-Radtke, H.Barton Grossman. (2003) Neoadjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations 21:6, 464-467
     CrossRef

127. 127

     S.Machele Donat. (2003) Evaluation and follow-up strategies for superficial bladder cancer. Urologic Clinics of North America 30:4, 765-776
     CrossRef

128. 128

     John P Stein. (2003) Indications for early cystectomy. Urology 62:4, 591-595
     CrossRef

129. 129

     J. Bellmunt, R. de Wit, S Albiol, J Tabernero, J Albanell, J Baselga. (2003) New drugs and new approaches in metastatic bladder cancer. Critical Reviews in Oncology/Hematology 47:2, 195-206
     CrossRef

130. 130

     Sana Al-Sukhun, Maha Hussain. (2003) Molecular biology of transitional cell carcinoma. Critical Reviews in Oncology/Hematology 47:2, 181-193
     CrossRef

131. 131

     Richard J. Cote, Ram H. Datar. (2003) Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Critical Reviews in Oncology/Hematology 46, 67-83
     CrossRef

132. 132

     John RW Masters, Urvi D Vani, Kenneth M Grigor, Gareth O Griffiths, Angela Crook, Mahesh KB Parmar, Margaret A Knowles, . (2003) Can p53 staining be used to identify patients with aggressive superficial bladder cancer?. The Journal of Pathology 200:1, 74-81
     CrossRef

133. 133

     NORM D. SMITH, JONATHAN N. RUBENSTEIN, SCOTT E. EGGENER, JAMES M. KOZLOWSKI. (2003) The p53 Tumor Suppressor Gene and Nuclear Protein: Basic Science Review and Relevance in the Management of Bladder Cancer. The Journal of Urology 169:4, 1219-1228
     CrossRef

134. 134

     Sergiusz Nawrocki, Tomas Skacel, Thomas Brodowicz. (2003) From microarrays to new therapeutic approaches in bladder cancer. Pharmacogenomics 4:2, 179-189
     CrossRef

135. 135

     Anthony J. Mutsaers, William R. Widmer, Deborah W. Knapp. (2003) Canine Transitional Cell Carcinoma. Journal of Veterinary Internal Medicine 17:2, 136-144
     CrossRef

136. 136

     Syed A Hussain, Nicholas D James. (2002) Organ preservation strategies in bladder cancer. Expert Review of Anticancer Therapy 2:6, 641-651
     CrossRef

137. 137

     Helen G Juffs, Malcolm J Moore, Ian F Tannock. (2002) The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. The Lancet Oncology 3:12, 738-747
     CrossRef

138. 138

     Sun I.l Kim, Soo Mee Kwon, Young Sig Kim, Sung Joon Hong. (2002) Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 60:5, 816-821
     CrossRef

139. 139

     Fabio Calabrò, Cora N. Sternberg. (2002) Localized and locally advanced bladder cancer. Current Treatment Options in Oncology 3:5, 413-428
     CrossRef

140. 140

     Debra Hawes, P.Y. Liu, Franco M. Muggia, Sharon Wilczynski, Richard Cote, Juan Felix, Keith Terada, Robert J. Belt, David S. Alberts. (2002) Correlation of p53 Immunostaining in Primary and Residual Ovarian Cancer at the Time of Positive Second-Look Laparotomy and its Prognostic Role: A Southwest Oncology Group Ancillary Study. Gynecologic Oncology 87:1, 17-23
     CrossRef

141. 141

     Achille Pich, Luigi Chiusa, Andrea Formiconi, Diego Galliano, Paola Bortolin, Alberto Comino, Roberto Navone. (2002) Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95:4, 784-790
     CrossRef

142. 142

     Nurcan Kilicli-Camur, Isin Kilicaslan, Mine G. Gulluoglu, Tarik Esen, Veli Uysal. (2002) Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathology International 52:7, 463-469
     CrossRef

143. 143

     Minetta C Liu, Edward P Gelmann. (2002) P53 gene mutations: Case study of a clinical marker for solid tumors. Seminars in Oncology 29:3, 246-257
     CrossRef

144. 144

     D Raghavan. (2002) Surgery and adjunctive chemotherapy for invasive bladder cancer. Surgical Oncology 11:1-2, 55-63
     CrossRef

145. 145

     MARK S. SOLOWAY, MARIO SOFER, ANIL VAIDYA. (2002) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The Bladder. The Journal of Urology1573-1583
     CrossRef

146. 146

     Mark S. Soloway, Mario Sofer, Anil Vaidya. (2002) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The Bladder. The Journal of Urology 167:4, 1573-1583
     CrossRef

147. 147

     A. Borkowski. (2002) Superficial bladder cancer T1G3: the choice of treatment. BJU International 89:6, 623-627
     CrossRef

148. 148

     Andrs Rodrguez-Alonso, Salvador Pita-Fernndez, Joaqun Gonzlez-Carrer, Jos Luis Nogueira-March. (2002) Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 94:6, 1677-1684
     CrossRef

149. 149

     FRANK REIHER, OZDEN OZER, MICHAEL PINS, BORKO D. JOVANOVIC, SCOTT EGGENER, STEVEN C. CAMPBELL. (2002) p53 AND MICROVESSEL DENSITY IN PRIMARY RESECTION SPECIMENS OF SUPERFICIAL BLADDER CANCER. The Journal of Urology 167:3, 1469-1474
     CrossRef

150. 150

     FRANK REIHER, OZDEN OZER, MICHAEL PINS, BORKO D. JOVANOVIC, SCOTT EGGENER, STEVEN C. CAMPBELL. (2002) p53 AND MICROVESSEL DENSITY IN PRIMARY RESECTION SPECIMENS OF SUPERFICIAL BLADDER CANCER. The Journal of Urology1469-1474
     CrossRef

151. 151

     Michael Peyromaure, Sun Weibing, Philippe Sebe, Patrice Verpillat, Marianne Toublanc, Marie-Christine Dauge, Laurent Boccon-Gibod, Vincent Ravery. (2002) Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology 59:3, 409-413
     CrossRef

152. 152

     Elizabeth L. Broghammer, Timothy L. Ratliff. (2002) Immunotherapy of urologic tumors. Urologic Oncology: Seminars and Original Investigations 7:2, 45-56
     CrossRef

153. 153

     R. Yiou, J.-J. Patard, H. Benhard, C.-C. Abbou, D.K. Chopin. (2002) Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU International 89:4, 374-378
     CrossRef

154. 154

     Pollack, Ian F., Finkelstein, Sydney D., Woods, Jeffrey, Burnham, Judith, Holmes, Emiko J., Hamilton, Ronald L., Yates, Allan J., Boyett, James M., Finlay, Jonathan L., Sposto, Richard, . (2002) Expression of p53 and Prognosis in Children with Malignant Gliomas. New England Journal of Medicine 346:6, 420-427
     Full Text

155. 155

     Martin Schuler. (2002) p53 Gene Therapy. American Journal of Cancer 1:1, 3-6
     CrossRef

156. 156

     I Kausch, A Böhle. (2002) Molecular Aspects of Bladder Cancer. European Urology 41:1, 15-29
     CrossRef

157. 157

     Gary D Grossfeld, Peter R Carroll, Neil Lindeman, Maxwell Meng, Susan Groshen, An-Chen Feng, Debra Hawes, Richard J Cote. (2002) Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology 59:1, 97-102
     CrossRef

158. 158

     Ming-Hsui Tsai, Chia-Der Lin, Yao-Yuan Hsieh, Florence Chi-Chen Chang, Fuu-Jen Tsai, Wen-Chi Chen, Chang-Hai Tsai. (2002) Prognostic Significance of the Proline Form of p53 Codon 72 Polymorphism in Nasopharyngeal Carcinoma. The Laryngoscope 112:1, 116-119
     CrossRef

159. 159

     Chi-Chen Chang, Yao-Yuan Hsieh, Fuu-Jen Tsai, Chang-Hai Tsai, Horng-Der Tsai, Cheng-Chieh Lin. (2002) The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertility and Sterility 77:1, 43-45
     CrossRef

160. 160

     Mark D. Hurwitz. 2002. Bladder Cancer: Assessment and Management. , 205-213.
     CrossRef

161. 161

     K.N Qureshi, T.R.L Griffiths, M.C Robinson, C Marsh, J.T Roberts, J Lunec, D.E Neal, J.K Mellon. (2001) Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. International Journal of Radiation Oncology*Biology*Physics 51:5, 1234-1240
     CrossRef

162. 162

     RABI TIGUERT, FERNANDO J. BIANCO, PETER OSKANIAN, YIWEI LI, DAVID J. GRIGNON, DAVID P. WOOD, J. EDSON PONTES, FAZLUL H. SARKAR. (2001) STRUCTURAL ALTERATION OF p53 PROTEIN IN PATIENTS WITH MUSCLE INVASIVE BLADDER TRANSITIONAL CELL CARCINOMA. The Journal of Urology2155-2160
     CrossRef

163. 163

     R Corey O’Connor, Nejd F Alsikafi, Gary D Steinberg. (2001) Therapeutic options and treatment of muscle invasive bladder cancer. Expert Review of Anticancer Therapy 1:4, 511-522
     CrossRef

164. 164

     Charles J Rosser, William F Benedict, Colin PN Dinney. (2001) Gene therapy for superficial bladder cancer. Expert Review of Anticancer Therapy 1:4, 531-540
     CrossRef

165. 165

     RABI TIGUERT, FERNANDO J. BIANCO, PETER OSKANIAN, YIWEI LI, DAVID J. GRIGNON, DAVID P. WOOD, J. EDSON PONTES, FAZLUL H. SARKAR. (2001) STRUCTURAL ALTERATION OF p53 PROTEIN IN PATIENTS WITH MUSCLE INVASIVE BLADDER TRANSITIONAL CELL CARCINOMA. The Journal of Urology 166:6, 2155-2160
     CrossRef

166. 166

     Toshiro Shirakawa, Ryohei Sasaki, Thomas A. Gardner, Chinghai Kao, Zhu-Jun Zhang, Kazuro Sugimura, Masafumi Matsuo, Sadao Kamidono, Akinobu Gotoh. (2001) Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-typep53 gene therapy compared to drug-sensitive cells. International Journal of Cancer 94:2, 282-289
     CrossRef

167. 167

     Fredrick S Leach. (2001) Molecular genetics of urothelial malignancies. Urologic Oncology: Seminars and Original Investigations 6:5, 211-219
     CrossRef

168. 168

     STEPHANIE J. KIELB, NIKHIL L. SHAH, MARK A. RUBIN, MARTIN G. SANDA. (2001) FUNCTIONAL p53 MUTATION AS A MOLECULAR DETERMINANT OF PACLITAXEL AND GEMCITABINE SUSCEPTIBILITY IN HUMAN BLADDER CANCER. The Journal of Urology 166:2, 482-487
     CrossRef

169. 169

     FRANK K. REIHER, MARINA ANOVICH, HANHUA HUANG, NORM D. SMITH, NOEL P. BOUCK, STEVEN C. CAMPBELL. (2001) THE ROLE OF HYPOXIA AND p53 IN THE REGULATION OF ANGIOGENESIS IN BLADDER CANCER. The Journal of Urology 165:6, 2075-2081
     CrossRef

170. 170

     Akira Irie, Toyoaki Uchida, Hironori Ishida, Kazumasa Matsumoto, Masatsugu Iwamura, Shiro Baba. (2001) p53 Mutation in Bladder Cancer Patients in Japan and Inhibition of Growth by in Vitro Adenovirus-Mediated Wild-Type p53 Transduction in Bladder Cancer Cells. Molecular Urology 5:2, 53-58
     CrossRef

171. 171

     James L. Prescott, Jim Montie, Tom W. Pugh, Terri McHugh, Robert W. Veltri. (2001) Clinical sensitivity ofp53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer 91:11, 2127-2135
     CrossRef

172. 172

     Yoshitaka Wada, Akinobu Gotoh, Toshiro Shirakawa, Katsuyuki Hamada, Sadao Kamidono. (2001) Gene Therapy for Bladder Cancer Using Adenoviral Vector. Molecular Urology 5:2, 47-52
     CrossRef

173. 173

     FRANK K. REIHER, MARINA ANOVICH, HANHUA HUANG, NORM D. SMITH, NOEL P. BOUCK, STEVEN C. CAMPBELL. (2001) THE ROLE OF HYPOXIA AND p53 IN THE REGULATION OF ANGIOGENESIS IN BLADDER CANCER. The Journal of Urology2075-2081
     CrossRef

174. 174

     Joel W Slaton, William F Benedict, Colin P.N Dinney. (2001) p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57:5, 852-859
     CrossRef

175. 175

     ANDREA HAITEL, BERND POSCH, MAHMOUD EL-BAZ, ALAA A. MOKHTAR, MARTIN SUSANI, MOHAMED A. GHONEIM, MICHAEL MARBERGER. (2001) BILHARZIAL RELATED, ORGAN CONFINED, MUSCLE INVASIVE BLADDER CANCER: PROGNOSTIC VALUE OF APOPTOSIS MARKERS, PROLIFERATION MARKERS, p53, E-CADHERIN, EPIDERMAL GROWTH FACTOR RECEPTOR AND c-erbB-2. The Journal of Urology 165:5, 1481-1487
     CrossRef

176. 176

     Jeffrey S Ross, Michael B Cohen. (2001) Detecting recurrent bladder cancer: new methods and biomarkers. Expert Review of Molecular Diagnostics 1:1, 39-52
     CrossRef

177. 177

     ANDREA HAITEL, BERND POSCH, MAHMOUD EL-BAZ, ALAA A. MOKHTAR, MARTIN SUSANI, MOHAMED A. GHONEIM, MICHAEL MARBERGER. (2001) BILHARZIAL RELATED, ORGAN CONFINED, MUSCLE INVASIVE BLADDER CANCER: PROGNOSTIC VALUE OF APOPTOSIS MARKERS, PROLIFERATION MARKERS, p53, E-CADHERIN, EPIDERMAL GROWTH FACTOR RECEPTOR AND c-erbB-2. The Journal of Urology1481-1487
     CrossRef

178. 178

     BRIAN J DUGGAN, JOHN D. KELLY, PATRICK F. KEANE, SAMUEL R JOHNSTON. (2001) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCER. The Journal of Urology946-954
     CrossRef

179. 179

     JAMES C. KIM, GARY D. STEINBERG. (2001) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER. The Journal of Urology 165:3, 745-756
     CrossRef

180. 180

     JAMES C. KIM, GARY D. STEINBERG. (2001) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER. The Journal of Urology745-756
     CrossRef

181. 181

     BRIAN J. DUGGAN, JOHN D. KELLY, PATRICK F. KEANE, SAMUEL R. JOHNSTON. (2001) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCER. The Journal of Urology 165:3, 946-954
     CrossRef

182. 182

     BADRINATH R. KONETY, ROBERT H. GETZENBERG. (2001) URINE BASED MARKERS OF UROLOGICAL MALIGNANCY. The Journal of Urology 165:2, 600-611
     CrossRef

183. 183

     Staffan Edstr??m, Elisabet Cvetkovska, Thomas Westin, Cecilia Young. (2001) Overexpression of p53-Related Proteins Predicts Rapid Growth Rate of Head and Neck Cancer. The Laryngoscope 111:1, 124-130
     CrossRef

184. 184

     Jeffrey S. Ross, Michael B. Cohen. (2001) Biomarkers for the Detection of Bladder Cancer. Advances in Anatomic Pathology 8:1, 37-45
     CrossRef

185. 185

     NEIL FLESHNER, LINDA KAPUSTA, DARREN EZER, SENDER HERSCHORN, LAURENCE KLOTZ. (2000) p53 NUCLEAR ACCUMULATION IS NOT ASSOCIATED WITH DECREASED DISEASE-FREE SURVIVAL IN PATIENTS WITH NODE POSITIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER. The Journal of Urology1177-1182
     CrossRef

186. 186

     Andrea R Florl, Knut H Franke, Dieter Niederacher, Claus-Dieter Gerharz, Hans-Helge Seifert, Wolfgang A Schulz. (2000) DNA Methylation and the Mechanisms of CDKN2A Inactivation in Transitional Cell Carcinoma of the Urinary Bladder. Laboratory Investigation 80:10, 1513-1522
     CrossRef

187. 187

     NEIL FLESHNER, LINDA KAPUSTA, DARREN EZER, SENDER HERSCHORN, LAURENCE KLOTZ. (2000) p53 NUCLEAR ACCUMULATION IS NOT ASSOCIATED WITH DECREASED DISEASE-FREE SURVIVAL IN PATIENTS WITH NODE POSITIVE TRANSITIONAL CELL CARCINOMA OF THE BLADDER. The Journal of Urology 164:4, 1177-1182
     CrossRef

188. 188

     A Nouri. (2000) Profile of p53 expression in bladder and oral tumours effects of in vitro manipulations of p53 on the behaviour of established human tumour cell lines. European Journal of Cancer 36:14, 1853-1862
     CrossRef

189. 189

     Catherine A Reznikoff, Somdatta Sarkar, Knut P Jülicher, Melissa S Burger, Jairaj A Puthenveettil, David F Jarrard, Michael A Newton. (2000) Genetic alterations and biological pathways in human bladder cancer pathogenesis. Urologic Oncology: Seminars and Original Investigations 5:5, 191-203
     CrossRef

190. 190

     Staffan Jahnson, Mats G. Karlsson. (2000) Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 89:3, 619-629
     CrossRef

191. 191

     Toshikatsu Hanada, Masayuki Nakagawa, Akio Emoto, Takeo Nomura, Nobuyoshi Nasu, Yoshio Nomura. (2000) Prognostic value of tumor-associated macrophage count in human bladder cancer. International Journal of Urology 7:7, 263-269
     CrossRef

192. 192

     Fredrick S. Leach, Jer-Tsong Hsieh, Kyle Molberg, M. Hossein Saboorian, John D. McConnell, Arthur I. Sagalowsky. (2000) Expression of the human mismatch repair gene hMSH2. Cancer 88:10, 2333-2341
     CrossRef

193. 193

     RONALD D. ENNIS, DANIEL P. PETRYLAK, PRIYA SINGH, EMILIA BAGIELLA, KATHLEEN M. O’TOOLE, MITCHELL C. BENSON, CARL A. OLSSON. (2000) THE EFFECT OF CYSTECTOMY, AND PERIOPERATIVE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN CHEMOTHERAPY ON THE RISK AND PATTERN OF RELAPSE IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER. The Journal of Urology 163:5, 1413-1418
     CrossRef

194. 194

     Jeffrey S. Ross, Michael B. Cohen. (2000) Ancillary methods for the detection of recurrent urothelial neoplasia. Cancer 90:2, 75-86
     CrossRef

195. 195

     Fumitaka Koga, Satoshi Kitahara, Kyoko Arai, Mikihiko Honda, Shuhei Sumi, Ken-ichiro Yoshida. (2000) Negative p53/Positive p21 Immunostaining Is a Predictor of Favorable Response to Chemotherapy in Patients with Locally Advanced Bladder Cancer. Cancer Science 91:4, 416-423
     CrossRef

196. 196

     Martin J Edelman, Frederick J Meyers, Tim R Miller, Stephen G Williams, Regina Gandour-Edwards, Ralph W deVere White. (2000) Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation. Urology 55:4, 521-525
     CrossRef

197. 197

     M. CRAIG HALL, YINGMING LI, REY-CHEN PONG, BRENT ELY, ARTHUR I. SAGALOWSKY, JER-TSONG HSIEH. (2000) THE GROWTH INHIBITORY EFFECT OF p21 ADENOVIRUS ON HUMAN BLADDER CANCER CELLS. The Journal of Urology 163:3, 1033-1038
     CrossRef

198. 198

     Deborah W. Knapp, Nita W. Glickman, Dennis B. DeNicola, Patty L. Bonney, Tsang L. Lin, Lawrence T. Glickman. (2000) Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations 5:2, 47-59
     CrossRef

199. 199

     N.Aydin Mungan, Lambertus A.L.M Kiemeney, Jos A.A.M van Dijck, Henk G van der Poel, J.Alfred Witjes. (2000) Gender differences in stage distribution of bladder cancer. Urology 55:3, 368-371
     CrossRef

200. 200

     M. CRAIG HALL, YINGMING LI, REY-CHEN PONG, BRENT ELY, ARTHUR I. SAGALOWSKY, JER-TSONG HSIEH &NA;. (2000) THE GROWTH INHIBITORY EFFECT OF p21 ADENOVIRUS ON HUMAN BLADDER CANCER CELLS. The Journal of Urology1033
     CrossRef

201. 201

     Alexandre R. Zlotta, Claude C. Schulman. (2000) BIOLOGICAL MARKERS IN SUPERFICIAL BLADDER TUMORS AND THEIR PROGNOSTIC SIGNIFICANCE. Urologic Clinics of North America 27:1, 179-189
     CrossRef

202. 202

     Jer-Tsong Hsieh, Colin P.N. Dinney, Leland W.K. Chung. (2000) THE POTENTIAL ROLE OF GENE THERAPY IN THE TREATMENT OF BLADDER CANCER. Urologic Clinics of North America 27:1, 103-113
     CrossRef

203. 203

     Farhang Rabbani, Carlos Cordon-Cardo. (2000) MUTATION OF CELL CYCLE REGULATORS AND THEIR IMPACT ON SUPERFICIAL BLADDER CANCER. Urologic Clinics of North America 27:1, 83-102
     CrossRef

204. 204

     KHAVER N. QURESHI, RAOUF N. G. NAGUIB, FREDDIE C. HAMDY, DAVID E. NEAL, J. KILIAN MELLON. (2000) NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. The Journal of Urology630
     CrossRef

205. 205

     KHAVER N. QURESHI, RAOUF N.G. NAGUIB, FREDDIE C. HAMDY, DAVID E. NEAL, J. KILIAN MELLON. (2000) NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. The Journal of Urology 163:2, 630-633
     CrossRef

206. 206

     Aria F. Olumi. (2000) A CRITICAL ANALYSIS OF THE USE OF p53 AS A MARKER FOR MANAGEMENT OF BLADDER CANCER. Urologic Clinics of North America 27:1, 75-82
     CrossRef

207. 207

     Shinji Yamamoto, Mitsuhiro Tada, Chyi Chia R. Lee, Chikayoshi Masuda, Hideki Wanibuchi, Rikio Yoshimura, Seiji Wada, Keisuke Yamamoto, Taketoshi Kishimoto, Shoji Fukushima. (2000) p53 Status in Multiple Human Urothelial Cancers: Assessment for Clonality by the Yeast p53 Functional Assay in Combination with p53 Immunohistochemistry. Cancer Science 91:2, 181-189
     CrossRef

208. 208

     VINATA B. LOKESHWAR, CAN ??BEK, HENRI T. PHAM, DAVID WEI, MARVIN J. YOUNG, ROBERT C. DUNCAN, MARK S. SOLOWAY, NORMAN L. BLOCK. (2000) URINARY HYALURONIC ACID AND HYALURONIDASE:. The Journal of Urology348
     CrossRef

209. 209

     VINATA B. LOKESHWAR, CAN ÖBEK, HENRI T. PHAM, DAVID WEI, MARVIN J. YOUNG, ROBERT C. DUNCAN, MARK S. SOLOWAY, NORMAN L. BLOCK. (2000) URINARY HYALURONIC ACID AND HYALURONIDASE: MARKERS FOR BLADDER CANCER DETECTION AND EVALUATION OF GRADE. The Journal of Urology 163:1, 348-356
     CrossRef

210. 210

     Mark J Krasna, You Sheng Mao, Joshua R Sonett, Gen Tamura, Ray Jones, Mohan Suntharalingam, Stephen J Meltzer. (1999) P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. The Annals of Thoracic Surgery 68:6, 2021-2024
     CrossRef

211. 211

     HIDEAKI MIYAKE, ISAO HARA, KAZUKI YAMANAKA, SOICHI ARAKAWA, SADAO KAMIDONO. (1999) SYNERGISTIC ENHANCEMENT OF RESISTANCE TO CISPLATIN IN HUMAN BLADDER CANCER CELLS BY OVEREXPRESSION OF MUTANT-TYPE p53 AND Bcl-2. The Journal of Urology 162:6, 2176-2181
     CrossRef

212. 212

     Neil Fleshner, JoAnne Garland, Alyson Moadel, Harry Herr, Jaimie Ostroff, Rene Trambert, Maryellen O'Sullivan, Paul Russo. (1999) Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 86:11, 2337-2345
     CrossRef

213. 213

     M. E. Craanen, P. Blok, G. J. A. Offerhaus, G. A. Meijer, W. Dekker, E. J. Kuipers, S. G. M. Meuwissen. (1999) p21Waf1/Cip1 expression and the p53/MDM2 feedback loop in gastric carcinogenesis. The Journal of Pathology 189:4, 481-486
     CrossRef

214. 214

     ELIZABETH A. PERALTA, XIPING LIU, TODD M. MCCARTY, TIMOTHY G. WILSON, DON J. DIAMOND, JOSHUA D.I. ELLENHORN. (1999) IMMUNOTHERAPY OF BLADDER CANCER TARGETING P53. The Journal of Urology 162:5, 1806-1811
     CrossRef

215. 215

     ELIZABETH A. PERALTA, XIPING LIU, TODD M. MCCARTY, TIMOTHY G. WILSON, DON J. DIAMOND, JOSHUA D. I. ELLENHORN. (1999) IMMUNOTHERAPY OF BLADDER CANCER TARGETING P53. The Journal of Urology1806
     CrossRef

216. 216

     Joseph J. Del Pizzo, Andrew Borkowski, Stephen C. Jacobs, Natasha Kyprianou. (1999) Loss of Cell Cycle Regulators p27Kip1 and Cyclin E in Transitional Cell Carcinoma of the Bladder Correlates with Tumor Grade and Patient Survival. The American Journal of Pathology 155:4, 1129-1136
     CrossRef

217. 217

     STEPHANE BERNARDINI, GERARD-L. ADESSI, CLAUDE BILLEREY, EVELYNE CHEZY, JEAN-PIERRE CARBILLET, HUGUES BITTARD. (1999) IMMUNOHISTOCHEMICAL DETECTION OF p53 PROTEIN OVEREXPRESSION VERSUS GENE SEQUENCING IN URINARY BLADDER CARCINOMAS. The Journal of Urology 162:4, 1496-1501
     CrossRef

218. 218

     STEPHANE BERNARDINI, GERARD-L. ADESSI, CLAUDE BILLEREY, EVELYNE CHEZY, JEAN-PIERRE CARBILLET, HUGUES BITTARD. (1999) IMMUNOHISTOCHEMICAL DETECTION OF p53 PROTEIN OVEREXPRESSION VERSUS GENE SEQUENCING IN URINARY BLADDER CARCINOMAS. The Journal of Urology1496-1501
     CrossRef

219. 219

     Knowles. (1999) The genetics of transitional cell carcinoma: progress and potential clinical application. BJU International 84:4, 412-427
     CrossRef

220. 220

     C. C. R. Lee, T. Ichihara, S. Yamamoto, H. Wanibuchi, K. Sugimura, S. Wada, T. Kishimoto, S. Fukushima. (1999) Reduced expression of the CDK inhibitor p27KIP1 in rat two-stage bladder carcinogenesis and its association with expression profiles of p21WAF1/Cip1 and p53. Carcinogenesis 20:9, 1697-1708
     CrossRef

221. 221

     C.-X. Pan, K.S. Koeneman. (1999) A novel tumor-specific gene therapy for bladder cancer. Medical Hypotheses 53:2, 130-135
     CrossRef

222. 222

     David G. Bostwick, Dharam Ramnani, Liang Cheng. (1999) DIAGNOSIS AND GRADING OF BLADDER CANCER AND ASSOCIATED LESIONS. Urologic Clinics of North America 26:3, 493-507
     CrossRef

223. 223

     CHRISTIAN PFISTER, JEAN MICHEL FLAMAN, FREDERICK DUNET, PHILIPPE GRISE, THIERRY FREBOURG. (1999) P53 MUTATIONS IN BLADDER TUMORS INACTIVATE THE TRANSACTIVATION OF THE P21 AND BAX GENES, AND HAVE A PREDICTIVE VALUE FOR THE CLINICAL OUTCOME AFTER BACILLUS CALMETTE-GUERIN THERAPY. The Journal of Urology 162:1, 69-73
     CrossRef

224. 224

     CHRISTIAN PFISTER, JEAN MICHEL FLAMAN, COSETTE MARTIN, PHILIPPE GRISE, THIERRY FREBOURG. (1999) SELECTIVE DETECTION OF INACTIVATING MUTATIONS OF THE TUMOR SUPPRESSOR GENE p53 IN BLADDER TUMORS. The Journal of Urology1973-1975
     CrossRef

225. 225

     CHRISTIAN PFISTER, JEAN MICHEL FLAMAN, COSETTE MARTIN, PHILIPPE GRISE, THIERRY FREBOURG. (1999) SELECTIVE DETECTION OF INACTIVATING MUTATIONS OF THE TUMOR SUPPRESSOR GENE p53 IN BLADDER TUMORS. The Journal of Urology 161:6, 1973-1975
     CrossRef

226. 226

     Haukaas, Daehlin, Maartmann-Moe, Ulvik. (1999) The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience. BJU International 83:9, 957-963
     CrossRef

227. 227

     Akihiko Takeda, Kazuaki Nakajima, Hideaki Shimada, Hideo Imaseki, Wataru Takayama, Hideki Hayashi, Takao Suzuki, Takenori Ochiai, Kaichi Isono. (1999) Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. Journal of Surgical Oncology 71:2, 112-116
     CrossRef

228. 228

     Peter W. Cooke, Nicholas D. James, Raji Ganesan, Michael Wallace, Andrea Burton, Lawrence S. Young. (1999) CD40 expression in bladder cancer. The Journal of Pathology 188:1, 38-43
     CrossRef

229. 229

     Armin Pycha, Christine Mian, Bernd Posch, Andrea Haitel, Alaa A Mokhtar, Mahmoud El-Baz, Mohamed A Ghoneim, Michael Marberger. (1999) Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators?. Urology 53:5, 1005-1010
     CrossRef

230. 230

     Van Brussel, Mickisch. (1999) Prognostic factors in renal cell and bladder cancer. BJU International 83:8, 902-909
     CrossRef

231. 231

     G A Niehans, R A Kratzke, M K Froberg, D M Aeppli, P L Nguyen, J Geradts. (1999) G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. British Journal of Cancer 80:8, 1175-1184
     CrossRef

232. 232

     Kimberly A Monnin, Igor B Bronstein, David K Gaffney, Joseph A Holden. (1999) Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p53 expression. Human Pathology 30:4, 384-391
     CrossRef

233. 233

     Jones, Fujiyama. (1999) Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU International 83:5, 535-556
     CrossRef

234. 234

     L. Dæhlin, S. Haukaas, H. Maartmann-Moe, P.C. Medby. (1999) Survival after radical treatment for transitional cell carcinoma of the bladder. European Journal of Surgical Oncology (EJSO) 25:1, 66-70
     CrossRef

235. 235

     Margaret A. Knowles. (1999) Identification of novel bladder tumour suppressor genes. Electrophoresis 20:2, 269-279
     CrossRef

236. 236

     D. Plastiras, G. Moutzouris, C. Barbatis, V. Presvelos, M. Petrakos, Ch. Theodorou. (1999) Can p53 nuclear over-expression, Bcl-2 accumulation and PCNA status be of prognostic significance in high-risk superficial and invasive bladder tumours?. European Journal of Surgical Oncology (EJSO) 25:1, 61-65
     CrossRef

237. 237

     James Prescott, Hitendra Patel, Shannon Tillman, Terri McHugh, David Ralph. (1999) Cleavage of double-stranded copy RNA by RNase 1 and RNase T 1 provides a robust means to detectp53 gene mutations in clinical specimens. Electrophoresis 20:6, 1149-1161
     CrossRef

238. 238

     HARRY W. HERR, DEAN F. BAJORIN, HOWARD I. SCHER, CARLOS CORDON-CARDO, VICTOR E. REUTER. (1999) CAN p53 HELP SELECT PATIENTS WITH INVASIVE BLADDER CANCER FOR BLADDER PRESERVATION?. The Journal of Urology 161:1, 20-23
     CrossRef

239. 239

     J.D. Kelly, K.E. Williamson, A.E. Irvine, P.W. Hamilton, H.P. Weir, N.H. Anderson, P.F. Keane, S.R. Johnston. (1999) Apoptosis and its clinical significance for bladder cancer therapy. BJU International 83:1, 1-10
     CrossRef

240. 240

     HARRY W. HERR, DEAN F. BAJORIN, HOWARD I. SCHER, CARLOS CORDON-CARDO, VICTOR E. REUTER. (1999) CAN p53 HELP SELECT PATIENTS WITH INVASIVE BLADDER CANCER FOR BLADDER PRESERVATION?. The Journal of Urology20-22
     CrossRef

241. 241

     Alfredo Santinelli, Renzo Ranaldi, Mariagrazia Baccarini, Bruno Mannella, Italo Bearzi. (1999) Ploidy, Proliferative Activity, p53 and bcl-2 Expression in Bronchopulmonary Carcinoids: Relationship with Prognosis. Pathology - Research and Practice 195:7, 467-474
     CrossRef

242. 242

     Derek Raghavan. (1998) EDITORIAL. The Journal of Urology1678-1679
     CrossRef

243. 243

     Derek Raghavan. (1998) EDITORIAL: BLADDER PRESERVATION IN PATIENTS WITH BLADDER CANCER-QUALITY VERSUS QUANTITY OF LIFE?. The Journal of Urology 160:5, 1678-1679
     CrossRef

244. 244

     Lang, Unteregger, Kartarius, GUnther, Bonkhoff, Montenarh, Zwergel. (1998) p53 autoantibodies in patients with urological tumours. BJU International 82:5, 721-726
     CrossRef

245. 245

     Keegan, Lunec, Neal. (1998) p53 and p53-regulated genes in bladder cancer. BJU International 82:5, 710-720
     CrossRef

246. 246

     Pierre-Paul Bringuier, Margaret McCredie, Guido Sauter, Michael Bilous, John Stewart, Michael J. Mihatsch, Paul Kleihues, Hiroko Ohgaki. (1998) Carcinomas of the renal pelvis associated with smoking and phenacetin abuse:p53 mutations and polymorphism of carcinogen-metabolising enzymes. International Journal of Cancer 79:5, 531-536
     CrossRef

247. 247

     COLIN P. N. DINNEY, ROBERT C. BABKOWSKI, MIGUEL ANTELO, PAUL PERROTTE, MONICA LIEBERT, HUA-ZHONG ZHANG, JUDY PALMER, ROBERT W. VELTRI, RUTH L. KATZ, H. BARTON GROSSMAN. (1998) RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. The Journal of Urology1285-1290
     CrossRef

248. 248

     S. JAHNSON, M. G. KARLSSON. (1998) PREDICTIVE VALUE OF p53 AND pRb IMMUNOSTAINING IN LOCALLY ADVANCED BLADDER CANCER TREATED WITH CYSTECTOMY. The Journal of Urology1291-1296
     CrossRef

249. 249

     Adshead, Kessling, Ogden. (1998) Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. BJU International 82:4, 503-512
     CrossRef

250. 250

     COLIN P.N. DINNEY, ROBERT C. BABKOWSKI, MIGUEL ANTELO, PAUL PERROTTE, MONICA LIEBERT, HUA-ZHONG ZHANG, JUDY PALMER, ROBERT W. VELTRI, RUTH L. KATZ, H. BARTON GROSSMAN. (1998) RELATIONSHIP AMONG CYSTECTOMY, MICROVESSEL DENSITY AND PROGNOSIS IN STAGE T1 TRANSITIONAL CELL CARCINOMA OF THE BLADDER. The Journal of Urology 160:4, 1285-1290
     CrossRef

251. 251

     S. JAHNSON, M.G. KARLSSON. (1998) PREDICTIVE VALUE OF p53 AND pRb IMMUNOSTAINING IN LOCALLY ADVANCED BLADDER CANCER TREATED WITH CYSTECTOMY. The Journal of Urology 160:4, 1291-1296
     CrossRef

252. 252

     Yasuhiro Hamada, Masahiro Mizoguchi, Satoshi O. Suzuki, Toru Iwaki. (1998) Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line. Brain Tumor Pathology 15:2, 77-82
     CrossRef

253. 253

     P. Blok, M. E. Craanen, W. Dekker, G. J. A. Offerhaus, G. N. J. Tytgat. (1998) No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. The Journal of Pathology 186:1, 36-40
     CrossRef

254. 254

     Wolfgang A. Schulz, Feliksas Jankevicius, Claus-Dieter Gerharz, Mayumi Kushima, Claudia van Roeyen, Helmut Bultel, Peter Gobell, Bernd J. Schmitz-Drager. (1998) Predictive Value of Molecular Alterations for the Prognosis of Urothelial Carcinoma. Cancer Detection <html_ent glyph="@amp;" ascii="&"/> Prevention 22:5, 422-429
     CrossRef

255. 255

     JOHN P. STEIN, GARY D. GROSSFELD, DAVID A. GINSBERG, DAVID ESRIG, JOHN A. FREEMAN, ARSENIO J. FIGUEROA, DONALD G. SKINNER, RICHARD J. COTE. (1998) PROGNOSTIC MARKERS IN BLADDER CANCER: A CONTEMPORARY REVIEW OF THE LITERATURE. The Journal of Urology 160:3, 645-659
     CrossRef

256. 256

     Yves Fradet, Yoshinobu Kubota, Jack A Schalken, Tokoaki Uchida, Osamu Yoshida. (1998) Genetic and molecular markers in the prognosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations 4:4-5, 139-144
     CrossRef

257. 257

     Jerome P. Richie, Aldo Bono, Louis J. Denis, M.A.S. Jewett, Tadao Kakizoe, Toshihiko Kotake, Tomoyuki Shirai, F.J.W. ten Kate. (1998) Tumor, nodes, metastasis (TNM) classification of bladder cancer. Urologic Oncology: Seminars and Original Investigations 4:4-5, 90-93
     CrossRef

258. 258

     M. M. Kirollos, S. McDermott, R. A. Bradbrook. (1998) Bladder tumor markers: Need, nature and application. 1 Nucleus-based markers. International Urogynecology Journal and Pelvic Floor Dysfunction 9:4, 221-227
     CrossRef

259. 259

     H Tsujii, M.K Gospodarowicz, M Bolla, K Fujita, M’Liss Hudson, N Mitsuhashi, J.T Roberts, J Shimazaki. (1998) The place of radiotherapy for localized invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations 4:4-5, 145-153
     CrossRef

260. 260

     Osen, FossA, Majak, ROtterud, Berner. (1998) Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. BJU International 81:6, 862-869
     CrossRef

261. 261

     JURGEN F. LINN, ISABELL SESTERHENN, FATHOLLAH K. MOSTOFI, MARK SCHOENBERG. (1998) THE MOLECULAR CHARACTERISTICS OF BLADDER CANCER IN YOUNG PATIENTS. The Journal of Urology 159:5, 1493-1496
     CrossRef

262. 262

     C.E. Salem, N.A. Tomasic, D.A. Elmajian, D. Esrig, P.W. Nichols, C.R. Taylor, D.G. Skinner, P. Roy-Burman, G. Lieskovsky, R.J. Cote. (1998) RE: p53 PROTEIN AND GENE ALTERATIONS IN PATHOLOGICAL STAGE C PROSTATE CARCINOMA. The Journal of Urology 159:5, 1648-1649
     CrossRef

263. 263

     EDWARD J. KIRSH, DAVID A. BAUNOCH, WALTER M. STADLER. (1998) EXPRESSION OF BCL-2 AND BCL-X IN BLADDER CANCER. The Journal of Urology1348-1353
     CrossRef

264. 264

     EDWARD J. KIRSH, DAVID A. BAUNOCH, WALTER M. STADLER. (1998) EXPRESSION OF BCL-2 AND BCL-X IN BLADDER CANCER. The Journal of Urology 159:4, 1348-1353
     CrossRef

265. 265

     Robin T. Vollmer, Peter A. Humphrey, Paul E. Swanson, Mark R. Wick, M'Liss A. Hudson. (1998) Invasion of the bladder by transitional cell carcinoma. Cancer 82:4, 715-723
     CrossRef

266. 266

     Yoshiyuki Kakehi, Enver Ozdemir, Tomonori Habuchi, Hirohiko Yamabe, Takayuki Hashimura, Yoshitaka Katsura, Osamu Yoshida. (1998) Absence of p53 Overexpression and Favorable Response to Cisplatin-based Neoadjuvant Chemotherapy in Urothelial Carcinomas. Cancer Science 89:2, 214-220
     CrossRef

267. 267

     Gregers G. Hermann, Thomas Horn, Kenneth Steven. (1998) THE INFLUENCE OF THE LEVEL OF LAMINA PROPRIA INVASION AND THE PREVALENCE OF P53 NUCLEAR ACCUMULATION ON SURVIVAL IN STAGE T1 TRANSITIONAL CELL BLADDER CANCER. The Journal of Urology 159:1, 91-94
     CrossRef

268. 268

     Keiji Ogura, Shigeki Fukuzawa, Tomonori Habuchi, Osamu Ogawa, Osamu Yoshida. (1997) Correlation of Nuclear Morphometry and Immunostaining for p53 and Proliferating Cell Nuclear Antigen in Transitional Cell Carcinoma of the Bladder. International Journal of Urology 4:6, 561-565
     CrossRef

269. 269

     Zivko Popov, Andras Hoznek, Marc Colombel, Sylvie Bastuji-Garin, Marie-Aude Lefrere-Belda, Jacqueline Bellot, Claude C. Abbou, Catherine Mazerolles, Dominique K. Chopin. (1997) The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80:8, 1472-1481
     CrossRef

270. 270

     Carlos Cordon-Cardo, Joel Sheinfeld, Guido Dalbagni. (1997) Genetic studies and molecular markers of bladder cancer. Seminars in Surgical Oncology 13:5, 319-327
     CrossRef

271. 271

     William H. Foresman, Edward M. Messing. (1997) Bladder cancer: Natural history, tumor markers, and early detection strategies. Seminars in Surgical Oncology 13:5, 299-306
     CrossRef

272. 272

     Luca Marini, Cora N. Sternberg. (1997) Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Urologic Oncology: Seminars and Original Investigations 3:5-6, 133-140
     CrossRef

273. 273

     Kokichi Sugano, Masakazu Tsutsumi, Yuki Nakashima, Kensei Yamaguchi, Hisanao Ohkura, Tadao Kakizoe, Takao Sekiya. (1997) Diagnosis of bladder cancer by analysis of the allelic loss of thep53 gene in urine samples using blunt-end single-strand conformation polymorphism. International Journal of Cancer 74:4, 403-406
     CrossRef

274. 274

     Li-Qun Jia, Motonobu Osada, Chikashi Ishioka, Makio Gamo, Shuntaro Ikawa, Takao Suzuki, Hideki Shimodaira, Tomohito Niitani, Toshio Kudo, Mitoshi Akiyama, Narimiti Kimura, Mitsuyoshi Matsuo, Hiroshi Mizusawa, Noriho Tanaka, Hideki Koyama, Masayoshi Namba, Ryunosuke Kanamaru, Toshio Kuroki. (1997) Screening thep53 status of human cell lines using a yeast functional assay. Molecular Carcinogenesis 19:4, 243-253
     CrossRef

275. 275

     Dan Theodorescu, Stanford R. Broder, James C. Boyd, Stacey E. Mills, Henry F. Jr Frierson. (1997) p53, bcl-2 and Retinoblastoma Proteins as Long-Term Prognostic Markers in Localized Carcinoma of the Prostate. The Journal of Urology 158:1, 131-137
     CrossRef

276. 276

     David A. Corral, Christopher J. Logothetis. (1997) New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World Journal of Urology 15:2, 139-143
     CrossRef

277. 277

     Carlos Cordon-Cardo, Joel Sheinfeld. (1997) Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World Journal of Urology 15:2, 112-119
     CrossRef

278. 278

     Mika-P. Raitanen, Teuvo L. J. Tammela, Matti Kallioinen, Jorma Isola. (1997) P53 Accumulation, Deoxyribonucleic Acid Ploidy and Progression of Bladder Cancer. The Journal of Urology1250-1253
     CrossRef

279. 279

     Mika-P. Raitanen, Teuvo L.J. Tammela, Matti Kallioinen, Jorma Isola. (1997) P53 Accumulation, Deoxyribonucleic Acid Ploidy and Progression of Bladder Cancer. The Journal of Urology 157:4, 1250-1253
     CrossRef

280. 280

     Takeshi Inagaki, Shoichi Ebisuno, Yasunari Uekado, Atsuyuki Hirano, Akihisa Hiroi, Toshiaki Shinka, Tadashi Ohkawa. (1997) PCNA and p53 in Urinary Bladder Cancer: Correlation with Histological Findings and Prognosis. International Journal of Urology 4:2, 172-177
     CrossRef

281. 281

     Francis X. Keeley, Marluce Bibbo, Peter A. McCue, Demetrius H. Bagley. (1997) Use of p53 in the diagnosis of upper-tract transitional cell carcinoma. Urology 49:2, 181-186
     CrossRef

282. 282

     Masakazu Tsutsumi, Kokichi Sugano, Kensei Yamaguchi, Tadao Kakizoe, Hideyuki Akaza. (1997) Correlation of Allelic Loss of the P53 Gene and Tumor Grade, Stage, and Malignant Progression in Bladder Cancer. International Journal of Urology 4:1, 74-78
     CrossRef

283. 283

     T. J. O. Liukkonen, P. K. Lipponen, M. Helle, K. E. Jauhiainen, . (1997) Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Urological Research 25:1, 1-8
     CrossRef

284. 284

     F. C. Burkhard, R. Markwalder, G. N. Thalmann, U. E. Studer. (1997) Immunohistochemical determination of p53 overexpression. Urological Research 25:S1, S31-S35
     CrossRef

285. 285

     Adrian P. Ireland, Geoffrey W.B. Clark, Tom R. DeMeester. (1997) Barrett's Esophagus. Annals of Surgery 225:1, 17-30
     CrossRef

286. 286

     Neil E. Fleshner, Harry W. Herr, Andrew K. Stewart, Gerald P. Murphy, Curtis Mettlin, Herman R. Menck. (1996) The National Cancer Data Base report on bladder carcinoma. Cancer 78:7, 1505-1513
     CrossRef

287. 287

     Franca Pompetti, Paola Rizzo, Richard M. Simon, Boris Freidlin, Daphne J. Mew, Harvey I. Pass, Piero Picci, Arthur S. Levine, Michele Carbone. (1996) Oncogene alterations in primary, recurrent, and metastatic human bone tumors. Journal of Cellular Biochemistry 63:1, 37-50
     CrossRef

288. 288

     Ronald M Przygodzki, Cesar A Moran, Saul Suster, Mohammed A Khan, Patricia A Swalsky, Anke Bakker, Michael N Koss, Sydney D Finkelstein. (1996) Primary mediastinal and testicular seminomas: A comparison of k-ras-2 gene sequence and p53 immunoperoxidase analysis of 26 cases. Human Pathology 27:9, 975-979
     CrossRef

289. 289

     David Esrig, John A. Freeman, Donald A. Elmajian, John P. Stein, Su-Chiu Chen, Susan Groshen, Anne Simoneau, Eila C. Skinner, Gary Lieskovsky, Stuart D. Boyd, Richard J. Cote, Donald G. Skinner. (1996) Transitional Cell Carcinoma Involving the Prostate with a Proposed Staging Classification for Stromal Invasion. The Journal of Urology 156:3, 1071-1076
     CrossRef

290. 290

     David Esrig, John A. Freeman, Donald A. Elmajian, John P. Stein, Su-Chiu Chen, Susan Groshen, Anne Simoneau, Eila C. Skinner, Gary Lieskovsky, Stuart D. Boyd, Richard J. Cote, Donald G. Skinner. (1996) Transitional Cell Carcinoma Involving the Prostate with a Proposed Staging Classification for Stromal Invasion. The Journal of Urology1071-1076
     CrossRef

291. 291

     Hiroshi Okuno, Yoshiyuki Kakehi, Osamu Ogawa, Hitoshi Yamada, Enver Ozdemir, Yusaku Okada, Osamu Yoshida. (1996) Immunocytochemical Detection of p53 in Cultures of Exfoliated Cells from Urine of Patients with Urothelial Cancers. Cancer Science 87:7, 718-723
     CrossRef

292. 292

     Jeremy P. Crew, Timothy S. O'Brien, Adrian L. Harris. (1996) Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer and Metastasis Reviews 15:2, 221-230
     CrossRef

293. 293

     He Yu, Eleftherios P. Diamandis, Michael Levesque, Maurizia Giai, Riccardo Roagna, Riccardo Ponzone, Piero Sismondi, Maria Monne, Carlo M. Croce. (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research and Treatment 40:2, 171-178
     CrossRef

294. 294

     Seth H. Glick, Lydia P. Howell, Ralph W. Devere White. (1996) Relationship of p53 and bcl-2 to Prognosis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. The Journal of Urology 155:5, 1754-1757
     CrossRef

295. 295

     Bernard Tetu, Yves Fradet, Pierre Allard, Chantal Veilleux, Nancy Roberge, Pascale Bernard. (1996) Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer. The Journal of Urology1784-1788
     CrossRef

296. 296

     Bernard Tetu, Yves Fradet, Pierre Allard, Chantal Veilleux, Nancy Roberge, Pascale Bernard. (1996) Prevalence and Clinical Significance of Her-2/neu, p53 and Rb Expression in Primary Superficial Bladder Cancer. The Journal of Urology 155:5, 1784-1788
     CrossRef

297. 297

     Seth H. Glick, Lydia P. Howell, Ralph W. Devere White. (1996) Relationship of p53 and bcl-2 to Prognosis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. The Journal of Urology1754-1757
     CrossRef

298. 298

     Kamal Thapar, Bernd W. Scheithauer, Kalman Kovacs, Peter J. Pernicone, Edward R. Laws. (1996) p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions. Neurosurgery 38:4, 765-771
     CrossRef

299. 299

     Kamal Thapar, Bernd W. Scheithauer, Kalman Kovacs, Peter J. Pernicone, Edward R. Laws. (1996) p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions. Neurosurgery765-771
     CrossRef

300. 300

     Joseph Presti. (1996) Editorial. The Journal of Urology1004
     CrossRef

301. 301

     (1996) EDITORIAL COMMENT. The Journal of Urology 155:3, 892-893
     CrossRef

302. 302

     Joseph Jr. Presti. (1996) Editorial: Cost Conscious Evaluation and Treatment of Prostate Cancer. The Journal of Urology 155:3, 1004
     CrossRef

303. 303

     Brian C. S. Liu. (1996) Editorial Comment. The Journal of Urology892-893
     CrossRef

304. 304

     Catherine S. Wu, Alan Pollack, Bogdan Czerniak, Valerian Chyle, Gunar K. Zagars, Colin P.N. Dinney, Shi-Xue Hu, William E. Benedict. (1996) Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 47:3, 305-310
     CrossRef

305. 305

     Kalliopi P. Siziopikou, John E. Prioleau, Jay R. Harris, Stuart J. Schnitt. (1996) bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77:3, 499-506
     CrossRef

306. 306

     David Sidransky, M.D, Monica Hollstein, Ph.D. (1996) CLINICAL IMPLICATIONS OF THE p53 GENE. Annual Review of Medicine 47:1, 285-301
     CrossRef

307. 307

     Howard I. Scher. (1996) Editorial Comment. The Journal of Urology499-500
     CrossRef

308. 308

     Dan Theodorescu. (1996) Commentary on Genetic Prognostic Markers for Transitional Cell Carcinoma of the Bladder: From Microscopes to Molecules. The Journal of Urology 155:1, 2
     CrossRef

309. 309

     Dan Theodorescu. (1996) Commentary on Genetic Prognostic Markers for Transitional Cell Carcinoma of the Bladder. The Journal of Urology2
     CrossRef

310. 310

     Philip J. Walther. (1995) Editorial: “Wildcatting” for Breakthroughs in Urothelial Cancer Detection and Management-Frustrating Business. The Journal of Urology 154:4, 1348-1350
     CrossRef

311. 311

     Philip J. Walther. (1995) Editorial. The Journal of Urology1348-1350
     CrossRef

312. 312

     Ioannis Diamantis, Eva Karamitopoulou, Elias Perentes, Arthur Zimmermann. (1995) p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 22:3, 774-779
     CrossRef

313. 313

     John A. Freeman, David Esrig, John P. Stein, Anne R. Simoneau, Eila C. Skinner, Su-Chiu Chen, Susan Groshen, Gary Lieskovsky, Stuart D. Boyd, Donald G. Skinner. (1995) Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76:5, 833-839
     CrossRef

314. 314

     Timothy L. Ratliff. (1995) Commentary on Interleukin-6 and BCG Therapy. The Journal of Urology346
     CrossRef

315. 315

     Timothy L. Ratliff. (1995) Commentary on Interleukin-6 and BCG Therapy. The Journal of Urology 154:2, 346
     CrossRef

316. 316

     John A. Freeman, David Esrig, Gary D. Grossfeld, John P. Stein, Chen Su-Chiu, Lillian L. Young, Clive R. Taylor, Donald G. Skinner, Gary Lieskovsky, Richard J. Cote. (1995) Incidence of Occult Lymph Node Metastases in Pathological Stage C (pT3NO) Prostate Cancer. The Journal of Urology474-478
     CrossRef

317. 317

     John A. Freeman, David Esrig, Gary D. Grossfeld, John P. Stein, Chen Su-Chiu, Lillian L. Young, Clive R. Taylor, Donald G. Skinner, Gary Lieskovsky, Richard J. Cote. (1995) Incidence of Occult Lymph Node Metastases in Pathological Stage C (pT3NO) Prostate Cancer. The Journal of Urology 154:2, 474-478
     CrossRef

318. 318

     Howard B. Heidenberg, Isabell A. Sesterhenn, Jaya P. Gaddipati, Christopher M. Weghorst, Gregory S. Buzard, Judd W. Moul, Shiv Srivastava. (1995) Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer. The Journal of Urology414-421
     CrossRef

319. 319

     (1995) p53 and Bladder Cancer. New England Journal of Medicine 332:14, 957-958
     Full Text

Letters